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Delirium is a common syndrome amongst acutely unwell older adults. It is associated 
with significant morbidity and mortality, yet it remains poorly researched in the 
literature. Several theories have been proposed to explain the development of delirium 
but despite this the pathophysiology remains poorly understood. My thesis aims to 
addresses one such theory that has been little researched in the past; could delirium be 
associated with autonomic impairment? 
My thesis outlines the rationale for looking for such an association, including changes 
in cerebral perfusion and the role of acetylcholine. 
My study had a prospective case-control design. Participants were recruited while they 
were an inpatient with an acute illness in University Hospital Limerick. Diagnostic 
and Statistical Manual of Mental Disorders 4th Edition (DSM-IV) and Delirium Rated 
Scale Revised 1998 (DRS-R98) were used to evaluate for delirium. When the 
participant was free of acute illness a number of tests of autonomic function were 
carried out and consisted of a Head-Up Tilt test (HUT), baroreflex sensitivity testing 
measured using Baroreflex Effectiveness Index (BEI), 24-hour blood pressure 
variability (BPV), nocturnal blood pressure dipping status and 24-hour heart rate 
variability (HRV) measurements. A subgroup analysis of those without pre-existing 






During HUT the delirium group had a median decrease of 1mmHg (IQR 38.5) in 
systolic blood pressure compared to a median decrease of 17.5mmHg (IQR 20.75) in 
the control group (p=0.04). Increased delirium severity correlated with a reduction in 
the drop in systolic blood pressure during HUT (rs= -0.42, p=0.03). 
In those without pre-existing cognitive impairment, baroreflex sensitivity testing 
during HUT showed that increases in blood pressure were not followed by an 
appropriate corrective reduction in heart rate with a mean BEI of 36.87% (SD 22.26) 
in those with delirium and 56.03% (SD 23.04) in those without delirium (p=0.05). 
Nocturnal dipping status differed between the two groups during the subgroup 
analysis. 58.3% (7) of delirious participants were reverse dippers, 33.3% (4) were non-
dippers and 8.3% (1) had a normal dipping pattern. No participant was an extreme 
dipper. In the control group no participant was a reverse dipper, 57.1% (4) were non-
dippers, 14.3% (1) had a normal dipping pattern and 28.6% (2) were extreme dippers 
(p=0.01). 
BPV was measured by average real variability (ARV). In those without pre-existing 
cognitive impairment mean ARV was 13.81 (SD 5.98) in the control group and 9.69 
(SD 2.75) in the delirium group (p=0.05).  
HRV was measured using a 24-hour holter monitor. No difference was detected 
between the two groups. 
This study identifies differences in autonomic function between delirious participants 
and non-delirious controls, particularly when the impact of pre-existing cognitive 
impairment is excluded. This is the first study to look at several components of 
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1.0  Introduction to Thesis 
This thesis aims to look for evidence to support the hypothesis that there is an 
association between delirium and autonomic impairment. 
I will begin in Chapter 1 by providing an introduction to delirium epidemiology, 
clinical features and treatment. I will discuss the current theories that aim to explain 
the pathophysiology of delirium. Some of these theories form the basis for the 
hypothesis of this thesis. I will then provide an overview of the autonomic nervous 
system including physiology, clinical presentation of autonomic failure and some 
diagnostic tests used to evaluate for the presence of autonomic impairment. 
Taking the information presented in Chapter 1 into account, Chapter 2 outlines the 
rationale for looking for an association between delirium and autonomic impairment. 
It contains a literature review looking for previous research to support the hypothesis. 
Chapter 3 outlines the methods used in a prospective case-controlled study that aimed 
to test the hypothesis. This study forms the main component of this thesis. Chapter 4 
contains the results of this study and Chapter 5 discusses the results in the context of 








1.1 Introduction to Delirium 
Delirium is a condition associated with a global disturbance in cognition, inattention 
and perceptual disturbances, that is acute in onset and fluctuates in severity (Burns et 
al. 2004). Delirium is associated with adverse outcomes including increased in-
hospital mortality, twelve month mortality, length of hospital stay and rates of 
institutionalisation (Siddiqi et al. 2006; Witlox et al. 2010). Delirium has been shown 
to be associated with cognitive decline, particularly in individuals with dementia 
(Fong et al. 2009) and to be independently associated with poor functional outcomes 
after hip fracture (Marcantonio et al. 2000). Mortality rates have been reported to 
increase by 11% for every 48 hours of delirium (Gonzalez et al. 2009).  
Delirium can be described as a syndrome of acute brain failure (Daly 1980), for which 
there are numerous risk factors, causes and a myriad of underlying pathophysiological 
processes. Pre-existing chronic brain conditions make an individual more vulnerable 
to manifesting delirium, even with minor insults. 
 
1.2 Epidemiology of Delirium 
Delirium occurs commonly in hospitalised older adults. The incidence rate varies 
according to the population studied with an incidence of between 10% and 31% in 
medical inpatients (Siddiqi et al. 2006), up to 80% in some Intensive Care Unit (ICU) 
populations (Cavallazzi et al. 2012), 45% in oncology wards and 16% to 62% in 
patients with acute hip fracture (Kyziridis 2006). Delirium is also common in nursing 
home residents with an incidence of 20.7 per 100 person-years reported (Boorsma et 
al. 2012). Delirium often remains undiagnosed with one Irish prevalence study 






1.3 Pathophysiology of Delirium 
Various theories exist to explain the underlying pathophysiology of delirium but no 
single definitive mechanism has been shown. In certain cases the cause can be 
attributed to direct brain insults such as hypoxia, encephalitis, cerebral haemorrhage 
or cerebral infarction (MacLullich et al. 2008). However, in other cases such infections 
in remote sites, it is more difficult to ascertain the mechanism that leads to delirium.  
Delirium is more prevalent in older adults than their younger counterparts. It is 
therefore likely that the physiology of brain ageing is an important factor in delirium 
development (Flacker and Lipsitz 1999). It is known that in normal older adults there 
is cerebral atrophy (Skullerud 1985) and reduced cerebral perfusion (Krausz et al. 
1998; Parkes et al. 2004), with impaired mechanisms that maintain cerebral blood flow 
during fluctuations in blood pressure (Wagner et al. 2012). There is also age related 
neuronal loss particularly in the cerebral cortex (Walhovd et al. 2011). This altered 
physiology of the brain with ageing is compounded by the increased prevalence of 
brain disorders such as stroke, small vessel disease and Alzheimer’s pathology, 
thereby increasing the vulnerability of the brain to insults. Neurofilament light is a 
biomarker for neuroaxonal injury. Serum and CSF levels are higher in postoperative 
hip fracture delirious compared to non-delirious patients (Halaas et al. 2018). This 
suggests that delirium pathophysiology involves neuronal injury. 
 
Some of the main mechanisms proposed for delirium development are outlined below. 
 
1.3.1 Inflammatory Theory 
Infection at remote sites is one of the most common precipitants of delirium. 
Circulating inflammatory mediators, released in response to a systemic illness, can 






of prostaglandins and pro-inflammatory cytokines. This results is low level 
inflammation in the brain and could lead to the changes in cognitive function that 
occur in delirium (MacLullich et al. 2008).  
Several studies that look at levels of inflammatory markers in delirious patients 
support the inflammatory theory. C-Reactive Protein is an acute phase protein and is 
used widely is clinical practice as a marker of inflammation and infection. It has been 
shown to be more markedly raised in certain patients with delirium compared to those 
without delirium (Ritchie et al. 2014). Interlukin-6 levels are higher in delirious than 
non-delirious hip fracture patients (van Munster et al. 2010). Administration of 
Interlukin-2 can result in the development of delirium (Flacker and Lipsitz 1999). 
1.3.2 Neurotransmitter Abnormalities 
Acetylcholine is known to be involved in consciousness, attention and memory and a 
deficiency in acetylcholine is therefore thought to be involved in the pathophysiology 
of delirium.  Its levels normally decline with age, making older adults more susceptible 
to developing delirium (Ali et al. 2011). Administration of anti-cholinergic agents can 
induce delirium (Flacker and Lipsitz 1999) and increased anticholinergic activity has 
been shown to be associated with the development of delirium (Tune et al. 1981; 
Golinger and Tune 1987). However, serum anti-cholinergic activity levels can overlap 
significantly between delirious and non-delirious patients suggesting that other factors 
are involved (Flacker and Lipsitz 1999). 
Serotonin is an excitatory neurotransmitter in the brain involved in wakefulness, mood 
and cognition (Flacker and Lipsitz 1999).  It is derived from the amino acid precursor 
tryptophan (Lewis and Barnett 2004). Tryptophan crosses the blood brain barrier via 
completion with other large amino acids for the sodium independent LNAA 
transporter type 1 (Pandharipande et al. 2009). Thus if the proportion of another amino 






therefore reduced serotonin. Studies have shown reduced levels of tryptophan 
(Robinson et al. 2008) and an altered ratio of tryptophan to other large amino acids 
(Pandharipande et al. 2009) in patients with delirium. Melatonin is a tryptophan 
derived substance involved in the regulation of the sleep-wake cycle. Melatonin 
therapy has been shown to be effective in the prevention of delirium in patients with 
hip fracture (Al-Aama et al. 2011) and treatment of post-stroke delirium (Ohta et al. 
2013). This further supports the involvement of tryptophan in the pathophysiology of 
delirium.  
Dopamine levels can be increased during times of oxidative stress such as during an 
acute illness. This dopamine excess can lead to some of the features of delirium 
including hallucinations and delusions (Ali et al. 2011). The dopamine excess theory 
is supported by studies comparing homovanillic acid levels in patient with and without 
delirium. Homovanillic acid is the main dopamine metabolite and plasma levels show 
a significant correlation with cerebrospinal fluid (CSF) concentrations. Increased CSF 
homovanillic acid  concentrations are found in delirious patients (Ramirez-Bermudez 
et al. 2008). Plasma homovanillic acid levels are higher in delirious Alzheimer’s 
dementia patients than non-delirious Alzheimer’s dementia controls (van der Cammen 
et al. 2006). 
A combination of these neurotransmitter abnormalities may be involved in the 
development of delirium. 
1.3.3 Cortisol-Neuroendocrine Theory 
There is some evidence to support the hypothesis that elevated levels of cortisol may 
be involved in the pathogenesis of delirium. Increased stress, as a response to acute 
illness, can cause activation of the sympathetic nervous system, one of the effects of 
which is the release of cortisol. Excess cortisol has a negative impact on hippocampal 






2013) and a reduction in the normal diurnal variation in cortisol have been found in 
post-operative patients with delirium (Hall et al. 2016). Serum cortisol levels have 
been correlated to delirium severity in patients after an acute coronary syndrome 
(Colkesen et al.). CSF cortisol has also been shown to be higher in delirious than non-
delirious patients (Pearson et al. 2010). 
1.3.4 Cerebral Blood Flow and Oxidative Stress 
A reduction in cerebral blood flow could cause insufficient oxygenation of cerebral 
cells leading to cerebral dysfunction (Ali et al. 2011). Measures of oxygenation and 
oxidative stress have been found to be worse in patients with delirium than in controls 
(Seaman et al. 2006). Neopterin is a marker of oxidative stress. Levels are higher in 
abdominal surgery patients who develop delirium (Miao et al. 2018).  
Cerebral blood flow has been shown to be lower in patients during a delirious episode 
than after resolution (Yokota et al. 2003; Fong et al. 2006). In particular, cortical 
hypoperfusion has been identified using single-photon emission computed 
tomography (SPECT) scanning (Haggstrom et al. 2017). Continuous regional cerebral 
oxygenation monitoring using near-infrared spectroscopy suggests that cerebral 
autoregulation may be altered in delirium (Lee et al. 2018).  
Given the broad range of precipitants for delirium and the varied way in which it can 
present it is likely that delirium arises as a result of several of the above factors 
interacting, possibly with a common end pathway (van Munster and de Rooij 2014).  
 
1.4 Diagnosis of Delirium 
The Diagnostic and Statistical Manual of Mental Disorders (DSM) produced by the 






assessment has to be carried out by a trained professional following standardised 
testing.  
There are numerous different assessment scales in use in the clinical or research 
setting. The scales have a wide range of functions including delirium screening and 
diagnosis, assessment of arousability and screening for pre-morbid cognitive 
impairment.  
One of the most common delirium screening tools used in clinical practice is the 
Confusion Assessment Method (CAM). It is well validated with a sensitivity of 94-
100% and specificity of 90-95% (Wei et al. 2008). It has been adapted for use in the 
Intensive Care Setting (CAM-ICU) and is included in The National Institute for Health 
and Care Excellence (NICE) 2010 guidelines for delirium diagnosis (NICE 2010). The 
use of the CAM does however require appropriate training and can be difficult to apply 
quickly in the clinical setting. 
The 3D-CAM (3-Minute Diagnostic Assessment for Delirium) is based on the CAM 
algorithm. It stipulates observations and brief cognitive tests that should be used to 
inform diagnosis of each of the four criteria of the CAM. As the name suggests, it 
takes 3 minutes to complete, making it much quicker than the CAM. It has a sensitivity 
of 95% and specificity of 94% when compared to diagnosis made by DSM-IV criteria 
(Marcantonio et al. 2014). 
One of the best scales for quantifying delirium severity is the Delirium Rating Scale-
Revised 1998 (DRS-R98). This is based on the DSM criteria. It is more commonly 
used in the research setting as it is cumbersome to use in clinical practice.  
The 4AT is a newer screening tool. It is a validated, practical tool that is quick to 






practice, although it’s sensitivity (89.7%) and specificity (84.1%) are less those of the 
CAM (Bellelli et al. 2014). 
 
1.5 Clinical Features of Delirium 
Delirium develops over a short period of time, hours to days, and fluctuates in severity. 
Below are the most common features of delirium (Farley and McLafferty 2007; 
Saxena and Lawley 2009): 
1. Altered consciousness    
reduced arousal or hyper-vigilant 
2. Inattention 
reduced ability to concentrate and process information or is easily 
distracted 
3. Disorganised thinking 
confused, incoherent speech or lack of relevance of speech 
4. Perceptual disturbance 
hallucinations (predominately visual) or illusions 
5. Disturbance of sleep wake cycle 
6. Reduced orientation to time, place and person 
7. Disturbed visuospatial ability 
getting lost in familiar environment, impaired intersecting pentagons 
or clock drawing (bearing in mind that clock drawing involves 
numerous interacting cognitive processes including attention, planning 
and executive function) 
8. Urinary incontinence 
9. Gait impairment 
Inattention is a cardinal feature of delirium. Inattention can be obvious during a 
comprehensive patient assessment. Specific tests for inattention include the Months of 
the Year Backwards test. It is one of the most useful bedside tests for inattention 
(O'Regan et al. 2014). The test is commenced by asking the patient to recite the months 






patient to recite the months backwards starting with December. Inattention is 
considered present if they are unable to recite the months backwards as far as June.  
A range of motor subtypes of delirium have been described and include hyperactive 
delirium with increased level of activity with agitation, wandering, fidgeting or 
restlessness and hypoactive delirium with decreased activity and few spontaneous 
movements, decreased speed of actions, decreased amount or speed of speech, less 
reactive to their environment or detached from surroundings. Hypoactive delirium 
often goes unrecognised on medical wards and at home. (Meagher 2009) 
 
1.6 Factors that Precipitate or Predispose to Delirium 
There are numerous factors that can precipitate or cause delirium (Saxena and Lawley 
2009). The most common precipitating events for delirium can be grouped based on a 
modified version of the Delirium Etiology Checklist.  








Table 1: Precipitating Factors for Delirium 






Carbon monoxide poisoning 
Polypharmacy 
Drug Withdrawal Alcohol 
Hyponotics 
Benzodiazepines 
Metabolic/Endocrine Disturbances Electrolyte disturbances (e.g. 





B12, folate, thiamine deficiency 
Hypoxia or hypercapania 
Cardiovascular Myocardial infarction 
Cardiac failure 
Systemic infection At any other site, commonly urinary 
tract or respiratory tract 
Cerebrovascular Intracerebral haemorrhage 
Ischaemic stroke 
Organ Insufficiency Renal failure 
Liver failure 
Central Nervous System (CNS) Seizures 
Meningitis/encephalitis 













Demographics Older Age 







1.7 Treatment of Delirium 
The National Institute for Health and Care Excellence provide guidance for the 
treatment of delirium (NICE 2010). Identification and treatment of the underlying 
precipitants is essential. Delirious patients require continuous reassurance and 
reorientation. Involvement of family or carers is recommended. Patients should not 
move between wards or rooms unless absolutely necessary. Good sleep hygiene 
should be promoted. Treatment of the precipitating acute medical illness is required 
for the resolution of delirium.  
1.7.1 Antipsychotics 
Where patients have severe agitation or distress, delirium may require 
pharmacological management to allow for the delivery of essential medical treatment. 
Short term (less than on week) use of anti-psychotics  are considered for the treatment 
of distressed patients, who are a danger to themselves or others. Anti-psychotics 
should be used in caution in patients with Parkinson’s Disease and be avoided 
completely in Lewy Body Dementia. It is widely accepted in clinical practice that 
antipsychotics reduce agitation and distress in delirious patients. Despite this the 
evidence supporting the routine use of antipsychotics in clinical practice is lacking. A 
recent systematic review and meta-analysis (Neufeld et al. 2016) found that 
antipsychotic use was not associated with improved delirium severity, delirium 
duration, mortality or length of stay. The quality of studies included was poor. A well 
conducted randomised controlled trial in a high risk hospital population is required to 
inform practice. 
The choice of antipsychotic used can be tailored based on their sedative effects and 
available route of administration. Quetiapine (oral option only) and olanzapine (useful 
oral dissoluble wafer formulation) are more sedating whereas haloperidol and 






would be accepted as the least likely to aggravate Parkinson’s disease, although all 
antipsychotics should be avoided in Lewy Body Dementia. 
Where anti-psychotics are used it should be for the shortest duration and at the lowest 
effective dose. 
1.7.2 Benzodiazepines 
Benzodiazepines are less effective than antipsychotics for the treatment of delirium 
and have been shown to worsen delirium (Lonergan et al. 2009). They are also more 
likely to cause over-sedation (Attard et al. 2008). They have a particular role in certain 
circumstances such as alcohol withdrawal, benzodiazepine withdrawal or for 
managing severe agitation in patients with Lewy Body Dementia. Benzodiazepines 
are also useful as an adjunct to antipsychotics for severe agitation where patients are 
a danger to themselves or others. Lorazepam, as a short acting benzodiazepine, is a 
suitable choice in this situation (Saxena and Lawley 2009). Longer acting 
benzodiazepines such as diazepam or chlordiazepoxide are useful for alcohol 
withdrawal. In the settling of seizure related delirium, benzodiazepines are a better 
option as antipsychotics lower seizure threshold and should be avoided. 
1.7.3 Acetylcholinesterase Inhibitors 
Acetylcholinesterase inhibitors are used in the treatment of Alzheimer’s dementia 
(McGleenon et al. 1999). Rivastigmine has been associated with increased mortality 
in ICU patients (Van Eijk et al. 2011) and currently has no place in the routine 
treatment of delirium. In the settling of delirium associated with Lewy Body dementia, 
rivastigmine has however been shown to be beneficial in treating some symptoms of 






There is no evidence to support the use of donepezil in the treatment of delirium. 
Studies evaluating the effect of donepezil in the prevention of postoperative delirium 
have failed to show a significant benefit over placebo (Liptzin et al. 2005; Sampson et 
al. 2007; Marcantonio et al. 2011). The studies however have small sample sizes and 
were likely insufficiently powered to detect a significant difference. 
1.7.4 Dexmedetomidine 
Dexmedetomidine is a highly selective alpha-2 receptor agonist that provides sedation, 
modest analgesia and reduces anxiety with minimal respiratory side effects. The 
pattern of sedation of alpha-2 agonists is quite different from that of other sedatives in 
that patients can be aroused readily and their cognitive performance on psychometric 
tests is usually preserved. Moreover, respiratory depression is less frequent. The most 
notable adverse effect is bradycardia. Alpha-2 agonists lack anticholinergic activity 
and promote a normal sleep pattern (Giovannitti et al. 2015).  
Dexmedetomidine is in routine clinical use in the ICU setting. It is indicated for 
patients requiring mild sedation, to a level where they remain responsive to verbal 
stimuli (Scott-Warren and Sebastian 2015). Nocturnal dexmedetomidine use is 
associated with more delirium free days in ICU patients compared to placebo (Skrobik 
et al. 2018). It is also associated with a lower delirium prevalence than that of sedation 
with midazolam. The dexmedetomidine group did however have a higher rate of 
bradycardia but a lower incidence of tachycardia and hypertension (Riker et al. 2009).  
1.7.5 Melatonin 
Some recent attention has been given to the role of melatonin in the development and 
treatment of delirium. Melatonin is a hormone produced by the pineal gland. It is 
involved in regulation of the sleep-wake cycle. Delirious patients may have lower 






operative plasma melatonin levels are independently associated with the subsequent 
development of delirium (Chakraborti et al. 2015). Chakraborti et al performed a 
systematic review of the available evidence for the use of melatonin in the treatment 
of delirium. They identified one randomised controlled trial looking at delirium 
treatment and two looking at prevention. Incidence rates of delirium were lower in 
those treated with melatonin in the prevention studies. Delirium was successfully 
treated in 58% of patients in the treatment study. This was primarily a prevention study 
with all patients who developed delirium commenced on melatonin, there was 
therefore no comparative treatment group. 
 
1.8 Delirium Summary 
Delirium is a serious illness that presents with acute cerebral dysfunction. It is 
associated with adverse outcomes such as increased mortality and functional 
impairment leading to hospitalisation. The underlying pathophysiology is poorly 
understood and is likely multifactorial. The benefits of treatment have been poorly 
defined due to the difficulties in performing a stringent randomised controlled trial in 
a group of frail unwell older people, often with multiple co-morbidities and 
polypharmacy. The poorly understood underlying pathophysiology and the lack of 
evidence for effective treatments, compounded by the high prevalence and serious 







1.9 Introduction to the Autonomic Nervous System 
The autonomic nervous system controls involuntary, physiological processes in the 
body including respiration, endocrine and exocrine glands, bladder contractility, 
digestion and cardiovascular function (McCorry 2007). The autonomic nervous 
system consists of afferent, connector and efferent neurons. The afferent neurons 
originate in effector organs and travel to the central nervous system (CNS) where they 
are integrated via connector neurons (Snell 2010). Responsible areas of the brain 
include the hypothalamus and the brain stem (McCorry 2007). A response is generated 
through impulses to the effector organs via efferent pathways (Snell 2010).  
Efferent pathways, as shown in Figure 1, are made up of preganglionic and 
postganglionic neurons. The preganglionic neuron originates in the CNS in the lateral 
horn of the brainstem or spinal cord. Its axon synapses with the postganglionic neuron, 
which is located outside the CNS. The postganglionic neuron innervates the effector 
stem organ (McCorry 2007). 
There are two divisions of the autonomic nervous system-the sympathetic nervous 
system and parasympathetic nervous system. Many organs have input from both 
systems with the sympathetic and parasympathetic systems having antagonistic 










Figure 1: Efferent Pathways and Neurotransmitters of the Autonomic Nervous 
System 
 
Figure 1 shows the efferent pathways of the autonomic nervous system and the neurotransmitters released at each synapse. 
Norepinephrine=noradrenaline, epinephrine=adrenaline. Ach=acetylcholine. Reprinted from Encyclopædia Britannica. 
Available at https://www.britannica.com/science/preganglionic-neuron/media/474696/1154. Accessed March 2019. 
 
1.9.1 Sympathetic Nervous System 
The sympathetic nervous system is the larger of the two parts of the autonomic nervous 
system and is present in the heart, lungs, blood vessel walls, hair follicles, sweat glands 
and many abdominal organs. It is involved in ‘the flight or fight’ response or in the 
preparation of the body for an emergency. It increases heart rate, constricts blood 
vessels of the skin and intestine, dilates skeletal muscle vasculature, increases blood 
pressure, dilates pupils, dilates the bronchi, inhibits smooth muscle contraction and 
closes sphincters of the bladder and bowel (Snell 2010). It also controls ejaculation 






Preganglionic nerve bodies of the sympathetic nervous system are in the 
intermediolateral horn of the spinal cord from T1 to L2. Their neurons synapse with 
the sympathetic ganglia which are located adjacent to the spine. The neurotransmitter 
acetylcholine is involved in the transmission (Figure 1). The postganglionic neurons 
then travel to the effector organ. In most cases the postganglionic neurons release the 
neurotransmitter noradrenaline. Some nerve endings, particularly those transmitting 
to sweat glands and the blood vessels in skeletal muscles, release acetylcholine 
(McCorry 2007).  
Figure 2 shows the organ innervations of the sympathetic nervous system. 
1.9.2 Parasympathetic Nervous System 
The parasympathetic nervous system is involved in conserving energy. It slows the 
heart rate and increases peristalsis and glandular activity. In addition, it constricts the 
pupils, controls erectile function, contracts the bladder wall and opens sphincters 
(McCorry 2007; Snell 2010). 
Preganglionic nerve bodies of the parasympathetic nervous system are located in the 
brain stem and sacral part to the spinal cord. Parasympathetic ganglia are located in 
the effector organs (Figure 1). Both the preganglionic and postganglionic neurons 
release acetylcholine (McCorry 2007; Snell 2010). 









Figure 2: Sympathetic Nervous System 
 
Figure 2 shows the innervation of the sympathetic nervous system. Reprinted from the Merck Manual Professional Version. 











Figure 3: Parasympathetic Nervous System  
 
 
Figure 3 shows the innervation of the parasympathetic nervous system. Reprinted from the Merck Manual Professional 







1.9.3 Baroreceptor Function 
Baroreceptors are stretch-sensitive nerve fibres that are mainly located in the carotid 
sinuses and in the aortic arch. Additional baroreceptors are located in the heart and 
pulmonary vessels and are referred to as cardiopulmonary receptors. Baroreceptors 
form part of a negative feedback loop with the medulla that functions to maintain mean 
arterial pressure (MAP). Afferent fibres travel from the baroreceptors to the medulla, 
while efferent fibres travel from the medulla to the heart and smooth muscle of blood 
vessels via the sympathetic and parasympathetic nervous systems. An increase in 
MAP activates the baroreceptors. This leads to a reduction in sympathetic outflow to 
the heart and blood vessels. A reduction in MAP, as shown in Figure 4, relieves the 
stretch on the baroreceptors, increases sympathetic output and causes 







Figure 4: Baroreceptor Function 
 
Figure 4 contains a schemata explaining the role of baroreceptors when mean arterial pressure (MAP) decreases. The reverse 






1.10 Features of Autonomic Impairment 
Symptoms relating to the autonomic nervous system usually relate to loss of function 
or failure of the autonomic nervous system but autonomic hyperactivity can 
occasionally occur. Early symptoms can go unnoticed due to compensatory 
mechanisms (Donaghy 2009). Symptoms vary according to the system affected. For 
example, sympathetic adrenergic failure causes orthostatic hypotension (OH) and 
ejaculatory failure, while sympathetic cholinergic failure leads to loss of sweating. 
Parasympathetic failure causes dilated pupils, a fixed heart rate, urinary retention, an 
atonic large bowel and erectile dysfunction. With parasympathetic hyperactivity 
opposite features occur. In some disorders there may be a combination of effects, for 
example in neurally mediated syncope there is bradycardia caused by parasympathetic 
activity and hypotension resulting from withdrawal of sympathetic activity (Mathias 
2003). 
Some of the features of autonomic impairment are summarised below according to the 
system affected. 
1.10.1 Syncope 
Syncope is a transient loss of consciousness caused by a temporary reduction in 
cerebral blood flow. It can occur as a result of several disorders of the autonomic 
nervous system (Grubb 2005) as outlined below. 
Orthostatic hypotension 
Orthostatic hypotension (OH) is a decrease of at least 20 mm Hg in systolic blood 
pressure (SBP) or 10 mm Hg in diastolic blood pressure (DBP) on change of posture 
from lying to sitting or standing, or during the tilting phase of a head-up tilt (HUT) 
test (Mathias 2003; Lanier et al. 2011). During normal standing gravity causes blood 






sympathetic activity with vasoconstriction and increased peripheral vascular 
resistance, thereby reducing the amount of blood pooling and maintained blood 
pressure (Lanier et al. 2011). Orthostatic hypotension occurs when the sympathetic 
activity is not sufficient to allow this to occur (Goldstein and Sharabi 2009). 
Symptoms of orthostatic hypotension occur when the perfusion pressure of organs, 
particularly the brain, are not sufficient. Symptoms include dizziness, cognitive 
deficits and loss of consciousness. Symptoms vary significantly among people with 
similar blood pressure drops. This may be related to differences in cerebral 
autoregulation (Zygmunt and Stanczyk 2010). 
Neurocardiogenic Syncope 
 Activation of the sympathetic nervous system during standing results in increased 
contractility of the heart in an attempt to increase cardiac output. In neurocardiogenic 
syncope cardiac mechanoreceptors, which are normally activated during ventricular 
distension, are abnormally stimulated. This results in parasympathetic activation and 
sympathetic inhibition leading to reduced heart rate, reduced blood pressure and 
syncope. This can be diagnosed on HUT (Grubb 2005; Goldstein and Sharabi 2009), 
or in the setting of a typical clinical presentation. 
Carotid Sinus Hypersensitivity (CSH) 
Under normal circumstances stimulation of the carotid sinus results in reduced 
atrioventricular node conduction and reduced heart rate. In CSH this normal response 
is exaggerated. CSH is subdivided into 3 types-cardioinhibitory CSH, vasodepressor 
CSH and mixed CSH. Cardioinhibitory CSH is defined as asystole of 3 seconds or 
more. Vasodepressor CSH was defined as a drop of 50 mm Hg or more in systolic 






Postural Orthostatic Tachycardia Syndrome (POTS) 
POTS is a sustained increase in heart rate of at least 30 beats per minute (bpm) or to 
greater than 120 bpm on standing for 10 minutes. It is diagnosed using HUT. The 
pathogenesis of POTS involves impaired innervation of the peripheral vasculature or 
its inability to respond to the sympathetic nervous system. This leads to venous 
pooling in the extremities on standing, reduced venous return and a reflex tachycardia. 
It usually presents with palpitations, sweating, tremor and light-headedness on 
prolonged standing rather than syncope (Agarwal et al. 2007). 
1.10.2 Cardiovascular System 
Hypertension (HTN) 
Increased sympathetic activity or reduced parasympathetic activity can lead to 
hypertension. Increased circulating noradrenaline from sympathetic nerve terminals 
has been found in patients with familial hypertension. The number and aptitude of 
sympathetic bursts is also higher in those with familial and white coat hypertension. 
Components of heart rate variability (HRV) that reflect parasympathetic activity are 
lower in those with hypertension (Mancia and Grassi 2014). Severe paroxysmal 
hypertension can occur in those with high spinal cord lesions due to uninhibited 
sympathetic activation (Mathias 2003). 
Bradycardia 
Bradycardia can occur in high spinal cord lesions. The afferent and vagal efferent 
components of the baroreflex are intact and the heart rate slows in an attempt to reduce 






1.10.3 Genitourinary System 
Bladder 
During the storage phase of the micturition cycle the detrusor muscle relaxes to 
accommodate increasing volumes of urine and there is increased bladder outlet 
resistance. This is mediated by the sympathetic nervous system. In the voiding phase 
parasympathetic input causes detrusor contraction and reduces bladder outlet 
resistance (Ochodnicky et al. 2013). Loss of parasympathetic function causes an 
atonic bladder with urinary retention (Mathias 2003). Loss of sympathetic function 
would cause an increase in detrusor contraction leading to urinary frequency and 
incontinence. 
Ejaculation 
The sympathetic nervous system controls ejaculation by contracting the smooth 
muscle of the vas deferens, seminal vesicles and prostate (Snell 2010; Revenig et al. 
2014). Loss of sympathetic activity therefore leads to failure of ejaculation. 
Erectile Dysfunction 
The parasympathetic nervous system causes relaxation of the erectile tissue to the 
penis and clitoris. Loss of parasympathetic activity therefore causes erectile 
dysfunction (Snell 2010). 
1.10.4 Gastrointestinal Tract (GIT) 
The parasympathetic nervous system increases GIT activity by promoting peristalsis, 
increasing blood flow and increasing intestinal secretion. The sympathetic nervous 
system has opposing effects (Winge et al. 2003). Common symptoms of autonomic 







The parasympathetic nervous system supplies the salivary glands and causes an 
increase in salvation (Scully and Felix 2005) with dry mouth being a feature of reduced 
parasympathetic activity. 
Oesophagus 
In the oesophagus the parasympathetic nervous system provides motor innervation to 
the smooth muscle and secretomotor innervation to the glands. The sympathetic 
nervous system regulates blood vessel constriction, oesophageal sphincter contraction, 
relaxation of the muscular wall, and increases glandular and peristaltic activity (Kuo 
and Urma 2006). The main symptoms of autonomic dysfunction in the oesophagus are 
dysphasia and/or heartburn, which are due to impaired oesophageal mobility and 
gastro-oesophageal reflux (Bittinger et al. 1999).  
Stomach 
Activation of the sympathetic nervous system in the stomach causes constriction of 
the sphincters while the parasympathetic nervous system stimulates the smooth 
muscles for peristaltic movement and relaxes the sphincters (Browning and Travagli 
2011). Therefore, to empty the pylorus, sympathetic stimulation must be inhibited and 
the parasympathetic system must be excited. Delayed gastric emptying or 
gastroparesis are common manifestations of autonomic dysfunction. Common 
symptoms are nausea, vomiting or feelings or fullness (Bittinger et al. 1999). 
Bowel 
The parasympathetic nervous system promotes peristalsis and controls the external 








The sympathetic nervous system causes bronchodilation while the parasympathetic 
nervous system causes bronchoconstriction and gland secretion (Snell 2010). Stridor, 
snoring and nocturnal apnoea can occur in multiple systems atrophy (Mathias 2003). 
1.10.6 Body Temperature 
The sympathetic nervous system causes vasoconstriction of the blood vessels 
supplying the skin and increased secretion of sweat glands (Snell 2010). The inability 
to vasoconstrict, and therefore prevent heat loss, can result in hypothermia. Loss of 
sweating may prevent heat loss when exposed to high environmental temperatures and 
therefore cause a raised temperature (Mathias 2003).  
 
1.11 Causes of Autonomic Impairment 
In most incidences diseases related to the autonomic nervous system are sporadic, 
although genetic conditions such as familial dysautonomia do exist. Vasovagal 
syncope is often occupied by a family history especially in younger patients (Mathias 
2003). Most of the nerves of the autonomic nervous system are made up of small 
myelinated or unmyelinated fibres. Conditions that cause autonomic impairment are 
likely those that affect these small fibres (McDougall and McLeod 1996).  
Table 2 shows conditions that can result in autonomic dysfunction. In addition, 
medications such as levodopa or anti-hypertensives may unmask pre-existing 







Table 2: Causes of Autonomic Impairment 
Primary Acute/subacute 
dysautonomias 
Pure cholinergic dysautonomia 
Pure pandysautonomia 




Pure autonomic failure 
Multiple systems atrophy 
Autonomic failure with Parkinson’s disease 
Secondary Congenital Nerve growth factor deficiency 
Hereditary Familial amyloid neuropathy 
Porphyria 
Hereditary sensory and autonomic 
neuropathies 
Familial dysautonomia 
Metabolic diseases Diabetes mellitus 
Chronic renal failure 
Chronic liver failure 




Prion-fatal familial insomnia 
Neoplasm Brain tumours 






Systemic lupus erythematous 
Mixed connective tissue disease 
Surgery Regional sympathetomy 
Vagotomy 
Organ transplant 








1.12 Tests of Autonomic Function 
Many tests of autonomic function have been described however not all are suitable for 
routine clinical use (Donaghy 2009). Below is a description of some of the more 
practical to use tests. 
1.12.1 Active Stand and Head Up Tilt Testing 
Under normal circumstances, when an individual stands there is pooling of blood in 
the lower extremities. This activates baroreceptors and leads to increased sympathetic 
nervous system activity and peripheral vasoconstriction. A reduction of at least 
20mmHg in systolic blood pressure or 10 mmHg in diastolic blood pressure indicates 
abnormal sympathetic function (Lanier et al. 2011). In an active stand test blood 
pressure and heart rate are recorded while lying down. The participant then stands up 
while continued measurements are taken. During a HUT, the participant remains lying 
on the tilt table which is then raised to between 60° and 80°. This removes the effect 
that the peripheral musculature has on venous return. The only differences in 
haemodynamic responses between the two tests is seen after the initial change in 
posture (Zygmunt and Stanczyk 2010). 
1.12.2 Heart Rate Variability 
Heart Rate Variability (HRV) is the variation in time between consecutive R waves in 
the cardiac cycle (RR interval). Heart rate is partially under the control of the 
autonomic nervous system. High sympathetic activity and low parasympathetic 
activity results in an increased heart rate, with the reverse causing a reduced heart rate. 
The variability in heart rate therefore provides an insight into the function of the 
autonomic nervous system (Acharya et al. 2006). HRV can be assessed using 
ambulatory monitoring and from this a number of calculations can be carried out. 






or geometric measures (Task Force of The European Society of Cardiology and The 




Normal-to-normal (NN) intervals are the RR intervals arising from sinus node 
depolarisation (Peltola 2007). The SDNN is the standard deviation (SD) of all the NN 
intervals (Acharya et al. 2006). It is an estimate of overall HRV (ESC 1996). 
2. RMSSD 
RMSSD is the root mean square of successive difference of intervals (Acharya et al. 
2006). It is reflective of parasympathetic function (ESC 1996). 
3. pNN50 
This is the number of successive difference of intervals which differ by at least 50 
milliseconds expressed as a total of the number of electrocardiography (ECG) cycles 
included in the analysis (Acharya et al. 2006). It is reflective of parasympathetic 
function (ESC 1996). 
Geometric Measure- Triangular Index 
The triangular index is a geometric measure of overall HRV. It is assessed from a RR 
interval frequency distribution diagram by dividing the number of all RR intervals by 







Spectral analysis expresses heart rate as a function of frequency. It analyses the 
cyclical nature of changes in RR intervals. The frequency and magnitude of these 
changes are measured which allows separation of the data into different frequency 
components (Zygmunt and Stanczyk 2010). 
1. Low Frequency (LF) 
LF is contained in the range 0.04-0.15 Hertz (Hz) and is a measure of parasympathetic 
function. 
2. High Frequency (HF) 
HF is contained in the range 0.15-0.4 Hz and is a measure of parasympathetic function. 
 
3. LF/HF ratio 
The ratio reflects interactions of the sympathetic and parasympathetic nervous systems 
(ESC 1996; Zygmunt and Stanczyk 2010). 
 
1.12.3 Blood Pressure Variability 
Under normal physiological conditions changes in blood pressure occur as a 
regulatory response to environmental, emotional and behavioural stimuli. These short 
term blood pressure changes are mediated largely via changes in the sympathetic 
nervous system (Narkiewicz et al. 2002). Sustained increases in blood pressure 
variability (BPV) may reflect abnormalities in regulatory mechanisms such as 
impaired sympathetic or baroreflex function (Höcht 2013). Research has shown a 
direct relationship between higher sympathetic activity and greater BPV (Narkiewicz 






Several measures of BPV are available. The simplest measure is standard deviation, 
but this does not adequately reflect many important characteristics of BPV. It is largely 
impacted by night time fluctuations in blood pressure (Mena et al. 2017). It does not 
take into account the order in which blood pressure measurements are taken but rather 
examines their deviation from the mean (Pierdomenico et al. 2009). Average Real 
Variability (ARV) is an alternative measure of BPV and has been shown to be a better 
predictor of adverse outcomes (Mena et al. 2017).  
1.12.4 Sweating 
Lack of sweating can indicate impaired sympathetic function (Snell 2010). This can 
be tested by putting the patient’s hand into a plastic bag to prevent evaporation and 
then warming it under a light. Ponzo red, which turns red on getting wet, can be dusted 
onto the hand (Donaghy 2009). 
1.12.5 Valsalva Manoeuvre 
The Valsalva manoeuvre is induced by forced expiration against a closed glottis. 
Normally an increase in intrathoracic pressure causes a transient rise in blood pressure 
and by activating baroreceptors, also results in a slight bradycardia (phase 1). As 
venous return reduces, blood pressure decreases with a compensatory rise in heart rate 
(phase 2). When the expiration is stopped and the intrathoracic pressure is released, 
continued sympathetic drive causes the blood pressure to rise above the initial level 
and as result of baroreceptor activation heart rate falls below the initial rate (final 
phase). In autonomic failure this increase in blood pressure and fall of heart rate below 
the basal level do not occur (Donaghy 2009; Zygmunt and Stanczyk 2010).  
The Valsalva ratio can be calculated by dividing the longest RR interval in the final 






parasympathetic function while changes in blood pressure reflect sympathetic function 
(Zygmunt and Stanczyk 2010).  
1.12.6 Deep Breathing 
Heart rate response to breathing is mediated by the vagal nerve and thus provides a 
test of parasympathetic function. The subject is asked to breathe at a rate of 6 breaths 
per minute, with each inspiration and expiration lasting for 5 seconds. The respiratory 
sinus arrhythmia amplitude is the difference between the heart rate at the end of 
expiration and the end of inspiration. Normal values decrease with age with a 
minimum of 7 bpm for those over sixty years and over (Novak 2011). 
1.12.7 Isometric Handgrip Test 
The isometric handgrip test evokes a sympathetic reflex with a resultant rise is heart 
rate, systolic and diastolic blood pressure. Participants are asked to squeeze a 
dynamometer to obtain their maximum voluntary contraction. They are then asked to 
maintain a grip at 30-40% of this level for 3 to 5 minutes. Blood pressure 
measurements are taken every minute (Khurana and Setty 1996; Nielsen and Mather 
2015). In a normal test there should be a rise in diastolic blood pressure of at least 
15mmHg (Zygmunt and Stanczyk 2010). 
1.12.8 Cold Pressor Test 
A hand or foot is placed in water at a temperature of between 1° and 5°C. Afferent 
pain and temperature neurons are activated leading to activation of the sympathetic 
nervous system. In normal subjects there should be a rise in heart rate and blood 
pressure (Wirch et al. 2006). Diastolic blood pressure should rise by a minimum of 15 






1.13 Treatment of Autonomic Impairment 
Treatment of autonomic impairment largely depends on the predominant features 
present (McDougall and McLeod 1996) and is mainly targeted at treating the 
symptoms rather than the autonomic dysfunction itself (Kaufmann et al. 2015). Where 
an underlying condition has been identified this should also be treated if possible 
(McDougall and McLeod 1996). 
1.13.1 Treatment of Orthostatic Hypotension 
Treatment of OH include both pharmacological and non-pharmacological methods. 
Non-pharmacological methods include increasing fluid and salt intake to cause 
volume expansion and decreasing venous pooling through participation in physical 
activities (Figueroa et al. 2010). Although research is lacking for the benefit of their 
use, compression stocking are frequently used (Protheroe et al. 2011). Medications 
that are potentially contributing to hypotension, such as levodopa and alpha-blockers, 
should be eliminated where possible. Many patients require progression to 
pharmacological therapy (Kaufmann et al. 2015) as outlined below.   
Midodrine                                                                                                                         
Midodrine is a vasoconstrictor and increases erect blood pressure. As it has a short 
duration of action, a three-times a day dosing regime is recommended. The main side 
effect is supine hypertension and therefore the last dose should be taken in the 
afternoon in order to prevent nocturnal hypertension (Figueroa et al. 2010). 
Fludrocortisone 
Fludrocortisone is a synthetic mineralocorticoid that is of benefit in the treatment of 
orthostatic hypotension due to its ability to volume expand. It also increases vascular 






congestive cardiac failure and chronic renal failure. It can also cause hypokalaemia 
and supine hypertension (Figueroa et al. 2010). 
Pyridostigmine 
Pyridostigmine is an inhibitor of acetylcholinesterase that enhances ganglionic 
transmission in the sympathetic nervous system. It has been shown to increase 
orthostatic blood pressure and reduce orthostatic symptoms without worsening supine 
hypertension (Singer et al. 2006). 
Droxidopa 
Droxidopa is a synthetic amino acid that is converted into noradrenaline. It was 
approved by the American Food and Drug Administration in 2014 for the short-term 
treatment of neurogenic orthostatic hypotension. It has been shown to reduce 
symptoms of orthostatic hypotension and the impact that it has on daily life. The most 
common side effect reported is headache, although supine hypertension is another 
potential complication (Kaufmann et al. 2015). 
1.13.2 Treatment of GIT Symptoms 
Delayed gastric emptying may respond to prokinetic agents such as the dopamine 
antagonists metoclopramide and domperidone. Erythromycin, which is an agonist of 
the motilin receptor, can also be used as a prokinetic agent.  
Constipation should be treated with adequate hydration, high fibre diet and the use of 
laxatives. 
High fibre diet and bulking agents may also help with faecal incontinence (McDougall 






1.13.3 Treatment of Genitourinary Symptoms 
Urinary Retention  
Doxazosin is an alpha-adrenergic receptor blocker which may help reduce urinary 
retention by reducing bladder outlet pressure, but many patients will ultimately require 
catheterisation (McDougall and McLeod 1996; Duby et al. 2004). Doxazocin does 
have significant side effects and is often poorly tolerated by older adults due to its 
effects on blocking peripheral alpha-1 adrenoreceptors in vascular smooth muscle, 
which can cause or worsen orthostatic hypotension (Fulton et al. 1995). 
Erectile Dysfunction 
Medications that can contribute to sexual dysfunction such as beta-adrenoreceptor 
blocking agents and spironolactone should first be discontinued. Psychological factors 
should be addressed. A trial of a phosphodiesterase inhibitor, for example sildenafil, 
can be given if there are no contraindications (Duby et al. 2004) 
 
1.14 Summary of Autonomic Nervous System 
The autonomic nervous system is a complex system involved in maintaining normal 
body function. Autonomic impairment can have multiple potential causes. The clinical 
presentation is non-specific and can depend on the component of the autonomic 
nervous system affected. Treatment is largely targeted at symptom relief. 
 
1.15 Chapter Conclusion 
Chapter 1 has provided an overview of both the autonomic nervous system and 
delirium. Chapter 2 will now discuss the rationale for looking for an association 






Chapter 2: Rationale 












2.0 Prologue to Chapter 
Chapter 2 outlines the reasons for looking for an association between delirium and 
autonomic impairment. It examines potential links between the two conditions 
including altered cerebral perfusion, endothelial dysfunction and the role of 
acetylcholine. This chapter also details a literature review carried out to look for any 
previous studies that have investigated for a potential relationship.  
 
2.1 Cerebral Perfusion 
Adequate cerebral perfusion is required to provide sufficient oxygenation of cerebral 
cells and to prevent cerebral dysfunction (Ali et al. 2011). Measures of oxygenation 
and oxidative stress have been found to be worse in patients with delirium than in 
controls (Seaman et al. 2006). Other research suggests that delirium may be related to 
reduced cerebral perfusion (Ali et al. 2011). During cardiac surgery patients with 
higher systemic blood pressure, and therefore higher cerebral blood flow, have been 
shown to be less likely to develop post-operative delirium than those with lower 
perfusion pressures (Siepe et al. 2011). Similar results were shown for patients who 
had cerebral perfusion pressures measured during lung transplant surgery (Smith et al. 
2016). Studies based on neuroimaging have shown reduced cerebral blood flow in 
patients with delirium compared to after delirium resolution (Yokota et al. 2003; Fong 
et al. 2006). Cerebral blood flow declines with age (Donaghy 2009), which could 
potentially make older people more susceptible to delirium than their younger 
counterparts.   
Cerebral perfusion pressure is the difference between arterial and venous pressure in 
the brain. According to Poiseuielle’s law cerebral blood flow is directly related to 






(assumed to be constant). It is inversely related to the radius to the fourth power. Flow 
is calculated by using the following formula:  
Flow=(8nL)/r4, where n=blood viscosity, L=length of vessel, r=radius of vessel.  
Thus, small changes in the radius of a blood vessel can have a significant effect on 
cerebral blood flow. 
Cerebral autoregulation is the process by which the brain maintains a constant blood 
flow despite changes in perfusion pressure (Cipolla 2009). It does this through altering 
the blood vessel radius and therefore the resistance level of the vessel (Hu et al. 2008; 
Cipolla 2009). When cerebral perfusion pressure is in the range of 60 to 160mmHg, 
cerebral blood flow normally occurs at a rate of 50ml per 100g of brain tissue per 
minute. When cerebral perfusion pressure is outside of this range cerebral 
autoregulation is lost. At higher pressures cerebral perfusion pressure becomes 
dependent on mean arterial pressure in a linear fashion. At lower cerebral perfusion 
pressures there is initially a compensatory increase in oxygen extraction to maintain 
cerebral metabolic needs. When perfusion pressure falls sufficiently to prevent this, 
signs of hypoperfusion occur, such as altered mental status and dizziness (Cipolla 
2009). Thus patients with autonomic impairment and postural hypotension could have 
drops in their perfusion pressure at a level sufficient to fall below the autoregulatory 
range.  Previous research has shown that patients with known autonomic failure have 
lower cerebral blood flow during Head-Up Tilt testing than controls (Novak et al. 
1998). 
Cerebral autoregulation is affected by a number of factors including the autonomic 
nervous system and carbon dioxide levels. Sympathetic nervous system activation 
causes vasoconstriction and reduced cerebral blood flow while activation of the 






flow (Tameem and Krovvidi 2013). Cerebral autoregulation is disrupted in cerebral 
small vessel ischaemia, hypertension and diabetes (Guo et al. 2015). 
I therefore hypothesise that autonomic dysfunction could be associated with the 
development of delirium by causing sudden reductions in systemic blood pressure, 
and therefore reduced cerebral perfusion, and/or by disrupting cerebral autoregulation. 
 
2.2 Endothelial Dysfunction 
The endothelium is a single layer of cells that lines the lumen of blood vessels. It plays 
a role in the regulation of vascular tone, thrombosis and inflammation. The 
endothelium leads to vasodilation through the release of a number of vasoactive 
substances, the main one being nitric oxide. These substances lead to vasodilation 
through their interaction with the smooth muscle in the blood vessel wall. Cholinergic 
nerve endings of the autonomic nervous system are found in the endothelium and are 
coupled with the formation of nitric oxide, although the autonomic nervous system 
can regulate vasodilation even if nitric oxide is blocked. Endothelial dysfunction and 
autonomic impairment co-exist in several cardiovascular disease processes (Amiya et 
al. 2014).  
In a study investigating an association between endothelial dysfunction and delirium 
or coma among critically ill ICU patients, participants with endothelial dysfunction 
had less delirium or coma free days and longer durations of delirium. This suggests 
that endothelial dysfunction could play a role in the development of delirium (Hughes 






Given the role of the autonomic nervous system in endothelial function, further 
investigation into an association between delirium and the autonomic nervous system 
is justified. 
 
2.3 Role of Acetylcholine 
Acetylcholine is one of the two main neurotransmitters involved in the autonomic 
nervous system (McCorry 2007). It is also involved in attention and memory and a 
deficiency of acetylcholine is therefore thought to be involved in the pathophysiology 
of delirium (Ali et al. 2011). Administration of anti-cholinergic agents can induce 
delirium (Flacker and Lipsitz 1999) and increased anticholinergic activity has been 
shown to be associated with the development of delirium (Tune et al. 1981; Golinger 
and Tune 1987). Given the role of acetylcholine in the autonomic nervous system, 
further investigation to establish if there is an association between autonomic 
impairment and delirium is warranted.  
 
2.4 Review of the Available Literature 
A search of Pubmed, Embase, Cochrane Library, CINAHL and PsycINFO was carried 
out using PRISMA guidelines. Studies published before January 2017 were included. 
Titles and abstracts were searched using the search terms delirium, delirious, acute 
confusion, acute confusional state, encephalopathy, organic brain syndrome, brain 
dysfunction and brain failure which were cross-referenced with the terms autonomic 
nervous system, sympathetic nervous system, parasympathetic nervous system, 
autonomic function, sympathetic function, parasympathetic function, autonomic 






dysautonomia, heart rate variability, blood pressure variability, postural hypotension 
and orthostatic hypotension.  
Studies were included if they compared autonomic function in delirious participants 
to non-delirious controls, were clinical studies with human participants and had text 
available in English.  
Studies were excluded if they investigated confusion due to alcohol, drugs, traumatic 
brain injury, hypoxic brain injury or hepatic encephalopathy as the underlying 
pathophysiology may be different in these conditions.  
Of the 921 studies retrieved following removal of duplications, 916 were not related 
to the autonomic nervous system and delirium. Of the remaining 5 studies, 3 did not 
meet inclusion criteria leaving just 2 studies that investigated the relationship between 
autonomic impairment and delirium. The reference list of these studies was searched 
and no additional studies were identified. A summary of the study selection process is 
shown in Figure 5. 
One of the two studies found, Bolton et al (Bolton et al. 2007), investigated the 
relationship between various neurological disorders in the ICU and the autonomic 
nervous system. Sympathetic nervous system function was investigated using 
sympathetic skin response and parasympathetic function was investigated using heart 
rate variability (HRV).  Of the patients recruited, only two patients had delirium. The 
remaining participants had neurological conditions unrelated to delirium. They 
reported an abnormally fixed R-R interval and absent sympathetic skin response in the 
two patients with sepsis related delirium. The very small number of two delirious 







The second study retrieved, Zaal et al (Zaal et al. 2014), compared HRV in ICU 
patients with and without delirium. It was a prospective observational study. 
Participants from 30 to 80 years of age were recruited. Delirium screening was carried 
out using the Dutch version of the CAM-ICU. HRV was calculated using spectrum 
analysis of data collected over a 15 minute period. 13 patients with delirium and 12 
patients without delirium were included. Patients with delirium were older with a mean 
age of 67 compared to 57 years in the non-delirious group. There were more women 
in the delirium group (6 compared to 1). 69% of delirious patients and 50% of the 
controls were mechanically ventilated during the HRV recordings. Zaal et al reported 
no difference in HRV between the two groups. It is however worth noting the 
differences in age and gender between the two groups, both of which can impact on 
HRV (Zhang 2007). HRV has been shown to be lost during critical illness making 
patients in both groups susceptible to abnormalities in HRV (Buchman et al. 2002). In 
addition, HRV is altered during mechanical ventilation (Kasaoka et al. 2010). Given 
that over half of the patients in this study were mechanically ventilated, the 
generalisability of the results to all patients with delirium is limited.  This study 
remains important as it is the only study found that investigates a possible relationship 
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As outlined above there are several potential mechanisms that would support an 
association between autonomic impairment and delirium. Only one study has 
investigated this potential relationship and although no association was identified, the 
study was limited by the population studied and may not reflect the population of 
delirium patients as a whole. In addition, it only investigated HRV, a single test of 
autonomic function. Further investigation is therefore justified. This should take into 



















3.0  Prologue to Chapter 
This chapter outlines the study undertaken as part of this thesis to investigate for 
evidence of an association between autonomic impairment and delirium. It describes 
the study design, the aims and hypothesis of the study as well as detailing the study 
assessment tools used. 
 
3.1 Study Overview 
This study is an exploratory study to evaluate for a relationship between delirium and 
autonomic impairment. It is a prospective case control study with the cases being 
defined as participants who fulfilled diagnostic criteria for delirium and controls 
defined as participants who did not meet the diagnostic criterion. The diagnostic 
criteria are outlined in Section 3.10.2. 
 
3.2 Hypothesis of the Study 
The primary hypothesis of this study is that patients with delirium are more likely to 
have demonstrable autonomic dysfunction than patients without delirium, taking 
confounding factors such as age, severity of illness and medical comorbidities into 
account. 
 
Direct measurement of autonomic dysfunction is difficult, however there are well 
accepted surrogate measures and these include blood pressure variability, heart rate 
variability, abnormal diurnal blood pressure response and orthostatic blood pressure 
changes (as measured by tilt table testing). I hypothesise that individuals who 






heart rate variability, abnormal diurnal blood pressure profiles and a greater tendency 
to orthostatic blood pressure drops.  
 
3.3 Study Objectives 
The primary objective of the study is to assess if there is a relationship between 
delirium and autonomic dysfunction. 
If such a relationship is found, then the secondary objectives of the study are:  
1. To look for a relationship between the severity of delirium and severity of 
autonomic dysfunction 





Patients aged 65 years or older who were under the care of a consultant geriatrician 
were considered for inclusion. This was required in order to ensure that participants 
with previously undiagnosed cognitive impairment, that were detected during the 
course of the study, could be followed up on an ongoing basis.  The age criterion was 
applied to help ensure equal age distribution between the two groups as the incidence 
of delirium increases with age (Kukreja et al. 2015).  
 








A convenience sample of patients were selected on days in which the investigator was 
available to recruit participants. The geriatric teams identified potential participants 
who were medically appropriate for inclusion and did not meet any of the exclusion 
criteria. These individuals were made known to the investigator, who then invited 
them to participate. The inclusion and exclusion criteria used are shown in Table 3.  
 
 
Table 3: Study Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
• An inpatient at time 
of recruitment 
• Aged 65 years or 
older  
• Under the care of a 
consultant 
geriatrician 
• Medically unfit for assessment or requiring 
intensive care admission 
• Delirium due to alcohol or substance 
withdrawal where the underlying 
pathophysiology of delirium may be 
different 
• Co-morbid, uncontrolled moderate or 
severe depression as this may interfere 
with delirium assessments  
• Excessive drowsiness or coma  
• Severe expressive or receptive dysphasia 
as this may affect the ability to complete 
assessments 
• Co-morbid psychotic disorder 
• Patients deemed likely to require end of 
life treatment as assessed by a consultant 
geriatrician 
• Acute stroke or acute transient ischaemic 
attack as cerebral autoregulation may be 
disrupted 
• Intracerebral tumour as cerebral 
autoregulation may be disrupted 
• Acute myocardial infarction as heart rate 
variability may be altered 
• Inability to comply with Head-Up Tilt 
testing or ambulatory monitor testing 
• Inability to attend follow up 
 
Table 3 shows the inclusion and exclusion criteria for the study. Participants had to meet all the inclusion criteria and were 






3.5 Sample Size 
A systematic review of this topic was completed and there was no available literature 
on which to base a sample size calculation. As outlined in Chapter 2 one study was 
identified (Irene J. Zaal et al. 2014) that compared autonomic function in participants 
with delirium to normal controls. This was however carried out in an ICU population, 
which is different to the population of general older inpatients included in this study. 
Zaal et al used a single measure of autonomic function, short term heart rate 
variability. The present study uses different measures of autonomic function which are 
routinely collected during tilt table testing and 24-hour blood pressure and holter 
monitoring in our syncope unit. A formal sample size calculation based on the 
previous study was therefore not appropriate. As this was however the only available 
study, I did include a similar sample size in my study. I therefore aimed to carry out 
autonomic function testing on 25 participants. Given that the population included are 
older adults with comorbidities, I anticipated that not all participants initially recruited 
would attend for follow up. Recruitment was therefore continued until a sufficient 
number of participants had attended follow-up. 
As the sample size was small it was important to choose autonomic function tests with 
good reproducibility and low variability in results. Cardiovascular responses to HUT 
in a cohort of healthy, older adults were similar when carried out at baseline and six 
weeks (Youde et al. 2003). A previous retrospective review of patients attending our 
syncope unit showed that sit-to-stand blood pressure testing was not sensitive for the 
diagnosis of orthostatic hypotension as compared to HUT (Cooke et al. 2009). Heart 
rate variability measured over 24 hours is more reproducible than short term 
recordings (Morrin et al. 2017). 24-hour ambulatory systolic blood pressure 
monitoring is reproducible to within 2.8-3.8mmHg over four separate occasions 






3.6 Case Allocation 
Participants were assigned to either the case or control group following an assessment 
for delirium. Participants who meet all four DSM-IV criteria for delirium (see Section 
3.10.2) were recruited into the case/delirium group and those who did not meet all four 
diagnostic criteria were recruited to the control group. Thus participants with some, 
but not all features of delirium (subsyndromal delirium) may have been included in 
the control group. Use of the Delirium Rating Scale-Revised 1998 (DRS-R98) allowed 
the impact of the severity of subsyndromal delirium and delirium to be evaluated. 
 
3.7 Consent Process and Ethical Considerations 
Consent was obtained for all participants. Where a participant had capacity to provide 
consent, it was obtained from them. Where a participant did not have capacity to 
provide consent, in accordance with the Declaration of Helsinki, assent was obtained 
from their caregiver. If capacity returned during the study, informed consent was 
obtained from the participant. To avoid subjecting participants to repeated capacity 
tests, repeat testing was only carried out if capacity was suspected to have returned. 
Written consent was obtained where possible. Where a care-giver was unable to attend 
in person to sign an assent form, verbal assent over the phone was obtained. The 
consent form for participants can be found in Appendix A and the consent form for 
family members can be found in Appendix B. 
Participants or their family member received a written information leaflet (Appendix 
C) outlined the study objective, methods, risks and benefits. They were informed that 
they were under no obligation to participate in the study, they could withdraw consent 






Participants consented to the results of their study assessments being recorded in their 
medical notes and to be given to their primary consultant. This ensured that any 
abnormalities detected received further evaluation and treatment as required. 
Ethical approval for this study was received from University Hospital Limerick’s 
Research and Ethics Committee.  
 
3.8 Sequence of Events Following Recruitment and Consent 
The following demographic details were recorded at the initial assessment: 
• Date of birth 
• Date of admission 
• Date of assessment 
• Admission diagnosis 
• Past medical history 
• Medications 
3.8.1 Cognitive Assessment 
An evaluation for the presence of delirium was carried out using the Delirium Rating 
Scale-Revised 1998 (DRS-R98) and a diagnosis of delirium made using Diagnostic 
and Statistical Manual of Mental Disorders 4th Edition criteria (DSM-IV). DRS-R98 
was also used to assess delirium severity. The Delirium Motor Subtyping Scale 4 
(DMSS-4) was used to classify delirium into subtypes (hypoactive, hyperactive, mixed 






I carried out all of these assessments and completed appropriate training prior to the 
study commencing. Training was carried out by a psychiatrist who was experienced 
in the use of these tools in the research setting. 
3.8.2 Confounding Factors 
A number of assessments were carried out in order to identify major confounding 
factors that might impact on the study outcomes. The Eight Item Interview to 
Differentiate Aging and Dementia (AD8) was carried out to look for pre-existing 
cognitive impairment.  The severity of acute illness was classified based on the Acute 
Physiology and Chronic Health Evaluation II (APACHE II) scale. A 32 item Frailty 
Index (FI) (Appendix H), based on the Rockwood Frailty Index, was used to evaluate 
for the presence of frailty. The Modified Barthel Index was used to establish baseline 
functional status and the Charlson Comorbity Index was used to objectively measure 
comorbid illness. A description of these assessments can be found later in this chapter. 
3.8.3 Discharge 
Participants were discharged by their treating team when clinically appropriate. This 
was independent of study participation.  
3.8.4 Outpatient Follow-up  
Sepsis, acute illness and volume depletion would be likely to interfere with the 
measurement of autonomic function in the setting of an acute hospital admission. 
Therefore, autonomic function testing took place following discharge, at a time when 
the participant was free of an acute illness that could impact on the results.   
A Head-Up Tilt test took place to look for orthostatic hypotension or orthostatic 
hypertension. Continuous blood pressure and heart rate monitoring took place during 






baroreceptor effective index (BEI), which is a measure of BRS. A 24-hour ambulatory 
blood pressure monitor (ABPM) was completed to evaluate blood pressure variability 
(BPV) and the presence or absence of night-time reductions in blood pressure. A 24-
hour holter monitor was carried out to look for heart rate variability (HRV). 
A description of these assessments can be found later in this chapter. 
HUT and ambulatory monitoring were carried out by nurse specialists whose routine 
clinical work involves administering these tests.  I interpreted all test results, the 
process of which is part of my clinical practice.  




















Figure 6 shows an overview of the study process from participant recruitment to completion of autonomic function testing. 
Participants with some, but not all features of delirium (subsyndromal delirium), who therefore did not meet the DSM-IV criteria 
for delirium, were included in the control group. Use of the Delirium Rating Scale-Revised 1998 (DRS-R98) allowed the impact 
of the severity of subsyndromal delirium and delirium to be evaluated.
Inpatient identified to 
investigator as 
medically suitable for 
participation and 
meeting the inclusion 
and exclusion criteria 
Consent for inclusion 
obtained 
Demographics recorded 
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3.9 Data Management 
A pseudonymisation process was used in this study. Participants were assigned a study 
identification number following consent. A paper file was kept which contained the 
participant’s details and their assigned study identification number. This was kept in 
a locked filing cabinet, in a locked office in University Hospital Limerick. The study 
identification number was recorded on all assessments carried out.  
Assessments for delirium and confounding variables were recorded in paper format. 
Paper reports were generated for the autonomic function tests. All paper documents 
were kept in a locked cabinet, in a locked office in University Hospital Limerick.  
The onymous, original electronic reports for the autonomic function tests remained on 
the hospital’s secure, encrypted servers for use in clinical practice.  
Data was entered into Microsoft Excel and IBM Statistical Package for Social 
Sciences (SPSS) for analysis. The study identification number was used to label 
participants in these databases. 
 
3.10 Description of Study Assessments 
3.10.1 Delirium Rating Scale-Revised 1998 (DRS-R98) 
The DRS-R98 (Appendix D) is designed for the broad assessment of delirium. It can 
be used as both a diagnostic test for delirium and a valid and reliable rating scale for 
delirium severity. It is a 16-item scale with a 13-item severity section, which can be 
scored separately to the 3-item diagnostic section. The sum of the two sections allows 






Each item on the severity scale is rated 0 (absent/normal) to 3 (severe impairment). 
Severity scale scores range from 0 to 39, with higher scores indicating more severe 
delirium. There are three diagnostic items (rated 0-2 or 0-3). The total scale score 
ranges from 0 to 46 (Trzepacz et al. 2001). A diagnosis of delirium using DRS-R98 is 
made when the total score is greater than or equal to 18 in patients with co-morbid 
dementia or greater than or equal to 15 in patients without co-morbid dementia. Scores 
between 8 and 15 are considered subsyndromal delirium. 
DRS-R98 assessments are carried out using all available sources of information such 
as medical notes, patient assessment and collateral history from staff and family.  
The DRS-R98 has high inter- reliability, sensitivity and specificity for detecting and 
distinguishing delirium from mixed neuropsychiatric conditions such as dementia, 
depression and schizophrenia (Trzepacz et al. 2001). 
In this study the DRS-R98 was used to make an assessment for the presence of 
delirium and to rate the severity of delirium. The inattention section was evaluated 
using patient interaction and the Months Backwards test. This is a validated test to 
detect inattention in delirious patients (O’Regan et al. 2014). Short term memory was 
assessed by requesting the participant to recall three words. Clock drawing and 
copying intersecting pentagons was used to inform visuospatial ability scores 
(Trzepacz et al. 2001). 
3.10.2 Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition (DSM-
IV) 
The presence of delirium was confirmed if the participant fulfilled the criteria for 
delirium according to DSM-IV. The presence of all four criteria is required for a 






available data including admission notes, geriatric assessment, DRS-R98 assessment 
and collateral history from family and/or hospital staff involved in the care of the 
patient. 
The diagnostic criteria are shown in the Figure 7 below. 
 


















The presence of all four criteria above are required to confirm the diagnosis of delirium. 
 
 
3.10.3 Eight-Item Questionnaire to Differentiate Aging and Dementia (AD8) 
The AD8 (Appendix E) is a validated informant questionnaire that is sensitive for 
detecting both mild cognitive impairment and various types of dementia including 
A. A disturbance of consciousness (i.e. reduced clarity of 
awareness of the environment) with reduced ability to 
focus, sustain or shift attention. 
 
B. A change in cognition (such a memory deficit, 
disorientation, language disturbance) or the development 
of a perceptual disturbance that is not better accounted for 
by a pre-existing, established or evolving dementia. 
 
C. The disturbance develops over a short period of time 
(usually hours to days) and tends to fluctuate during the 
course of the day. 
 
D. There is evidence from the history, physical examination 
or laboratory findings that the disturbance is caused by the 








Alzheimer’s Disease, vascular dementia, Lewy Body dementia and frontotemporal 
dementia (Razavi et al. 2014). The AD8 is a formal, validated mechanism for obtained 
a collateral history from a family member. In this study the AD8 was used as part of 
the initial evaluation during the delirious episode in order to allow underlying 
cognitive impairment to be controlled for at a time with other evaluations such as the 
Montreal Cognitive Assessment (MoCA) would not be reliable. Compared to an 
alternative collateral questionnaire, the IQCODE, the AD8 has been shown to be equal 
in the detection of dementia but superior in detection of mild cognitive impairment 
(Razavi et al. 2014). The questionnaire was not carried out for participants who 
already had an established diagnosis of dementia. 
3.10.4 Abbreviated Delirium Motor Subtyping Scale (DMSS-4) 
The DMSS-4 was used to classify delirium into motor subtypes (hypoactive, 
hyperactive, mixed or none). It has a high concordance with the original, full DMSS 
(Meagher et al. 2014). In this study the DRS-R98 was used to inform classification of 
the motor subtype. 
3.10.5 Charlson Comorbidity Index 
Standardized documentation of comorbidities took place using the Charlson Co-
Morbidity Index (Appendix F). It is a validated tool used to measure burden of disease 
and one-year mortality risk. The index consists of 17 comorbidities (Roffman et al. 
2016). Extra points are added for older age groups, with one point added for those 
aged 50-59 years, 2 points added for those aged 60-69 years, 3 points for added for 
those aged 70-79 years and 4 points added for those aged 80 or above. 
3.10.6 Acute Physiology and Chronic Health Evaluation II (APACE-II) 
Illness severity was rated using the internationally accepted APACE-II scoring system 






different variables. The maximum score is 71, with a higher score being associated 
with greater disease severity and increased risk of death. While it has been validated 
mainly in ICU cohorts, it is widely researched and used to document severity of illness 
in the literature (Bouch and Thompson 2008). As an arterial blood gas is not routinely 
carried out in all patients, serum bicarbonate was substituted for arterial pH in 
participants with normal oxygenation (Wagner and Draper 1984).  
3.10.7 Frailty Index (FI) 
A Frailty Index measures frailty based on the number of health deficits that a person 
has accumulated. These deficits can take a wide range of forms including symptoms, 
diseases, disabilities, psychosocial factors or cognitive impairments. A minimum of 
30 items is required to make the frailty index valid. In order to be considered a deficit 
for a frailty index an item must meet 5 criteria. 
1. Must be associated with health status 
2. The prevalence of the deficit should in general increase with age 
3. Although the prevalence should increase with age it must not saturate too early 
4. The deficits as a group must cover a wide range of systems 
5. If a frailty index is used on the same person more than once the same list should 
be used each time 
The FI is calculated by dividing the total number of deficits a person has by the total 
number on the list (Searle et al. 2008). A FI of less than 0.08 is considered normal, FI 
of greater than 0.25 is considered frail and scores between these values are considered 
pre-frail.  
The frailty index used in this study can be found in Appendix H. It was measured 






3.10.8 Barthel Index 
The Barthel Index (Appendix I) is a measure of functional status. It records a person’s 
ability to carry out ten common activities of daily living. The maximum total score is 
100. A lower score indicates higher levels of dependency (Quinn et al. 2011).  
3.10.9 Head-Up Tilt (HUT) 
Head-up tilt testing is an investigation routinely used in the investigation of autonomic 
dysfunction. Patients lie supine on a bed for a period of three to five minutes. Supine 
blood pressure is recorded once blood pressure readings are stable. The tilt-table is 
then tilted to 70° with continuous beat-to-beat heart rate and blood pressure 
monitoring. This continues for 3 minutes. If blood pressure falls the lowest blood 
pressure reached is recorded. If blood pressure rises the steady state blood pressure is 
recorded. 
Orthostatic hypotension is defined as a drop in systolic blood pressure of at least 
20mmHg or a drop in diastolic blood pressure of at least 10mmHg. Orthostatic 
hypertension is defined as a rise in blood pressure by the same values.  
In this study HUT testing was carried out using CNSystems Task Force® Monitor. 
Testing took place on an outpatient basis when the participant was free of acute illness.  
3.10.10 Baroreceptor Sensitivity (BRS) 
The baroreceptor system plays an important role in the short-term blood pressure 
management and helps to prevent wide fluctuations in pressure. Changes in blood 
pressure are detected by stretch receptors in the carotid sinus and aortic arch. A 
reduction in blood pressure leads to increased sympathetic activity and reduced 
parasympathetic activity. Physiologically the result is increased heart rate, peripheral 






blood pressure. An increase in blood pressure detected by stretch receptors has the 
opposite effect (La Rovere et al. 2008). 
BRS testing took place at the same time as the HUT. BRS was measured using the 
Baroreflex Effectiveness Index (BEI). This is carried out by analysing beat-to-beat 
fluctuations in blood pressure and the corresponding changes in heart rate (La Rovere 
et al. 2008) or RR interval. The RR interval is the time between two consecutive R 
waves in the cardiac cycle.  
In this study continuous non-invasive blood pressure and heart rate monitoring were 
carried out using the Task Force ® Monitor from CNSystems. The build-in software 
identifies three or more consecutive beats where there is a progressive increase or 
decrease in blood pressure. It then looks at the changes in RR interval that accompany 
this. The BEI is the proportion of changes in blood pressure that are accompanied by 
an appropriate change in RR interval. This can be subdivided into increases in blood 
pressure accompanied by increases in RR interval (BEI-Up) and decreases in blood 
pressure accompanied be decreases in RR interval (BEI-Down).  
Participants were asked to lie supine for a period of three minutes with continuous 
monitoring. They were then placed in a 70° tilted position and monitoring was 
continued for a further three minutes. BEI was analysed separately for the supine and 
tilted periods.  
3.10.11 Blood Pressure Variability (BPV) 
As discussed in Section 1.12.3, blood pressure variability is a marker of sympathetic 
function. As Average Real Variability (ARV) is a better predictor of adverse outcomes 
than standard deviation (Mena et al. 2017), it was chosen as the measure of blood 






24-hour blood pressure monitoring (ABPM) took place when the participant was free 
of an acute illness that could impact on the results.  Blood pressure was recorded every 
15 minutes during the day and every 30 minutes at night. Individual blood pressure 
readings were entered into a spreadsheet (Microsoft Excel 2013). From these readings 
ARV was calculated using the formula: 
 
3.10.12 Diurnal Blood Pressure Variability 
Under normal circumstances there is a reduction in blood pressure at night by 10-20% 
(Calhoun and Harding 2010). This is associated with a reduction in sympathetic drive. 
The normal increase in blood pressure on awaking reflects activation of the 
sympathetic nervous system. Loss of night-time dipping in blood pressure reflects 
abnormally high levels of sympathetic activity (Sherwood et al.) and has been shown 
to correlate to worsening cardiovascular outcomes (Tsioufis et al. 2011).  
In this study, diurnal blood pressure changes were measured using the same 24-hour 
ambulatory monitor used to calculate ARV. Average daytime and night-time blood 
pressure readings were automatically calculated by the device. The percentage 
difference between the day and night-time measurements was calculated and used to 
define dipping status. Dipping status was classified as follows:  
Normal dipper: nocturnal blood pressure reduced by 10-20% 
Extreme dipper: nocturnal blood pressure reduced by greater than 20%  
Reverse dipper: nocturnal increase in blood pressure of at least 20%  







3.10.13 Heart Rate Variability (HRV) 
Heart rate is regulated by the interaction of the sympathetic and parasympathetic 
nervous systems. Activation of the parasympathetic system causes hyperpolarisation 
of cardiac pacemaker cells which reduces the rate of depolarisation and in turn reduces 
heart rate. Sympathetic activation has the opposite effect. HRV is a non-invasive 
measurement of autonomic nervous system function. In a normally functioning system 
there will be physiological variations in heart rate (Sztajzel 2004). 
HRV was recorded when the participant was free of acute illness using a 24-hour 
holter monitor. The data recorded was imported into Kubios HRV Standard which is 
a software package designed for calculating HRV (Tarvainen et al. 2014). Tracings 
were reviewed and non-sinus beats removed prior to analysis. The software then 
calculated HRV.  
As outlined in Section 1.12.2, there are various possible measures of HRV. Time 
domain measures use mathematical calculations based on the intervals between 
successive sinus beats. Two different time domain measures are used in this study, 
SDNN and RMSSD. SDNN is an estimate of overall HRV and RMSSD is reflective 
of parasympathetic function (ESC 1996). 
An alternative method of calculating HRV is using spectral analysis which expresses 
heart rate as a function of frequency. Low Frequency (LF) components are contained 
in the range of 0.04-0.15 Hertz (Hz) and are measure of sympathetic activity. High 
Frequency (HF) components are in the range of 0.15-0.4 Hz and are a measure of 
parasympathetic activity. The LF/HF ratio reflects interactions of the sympathetic and 






Various computerised algorithms are available for spectral analysis, the Fast Fourier 
Transform was the algorithm used by the Kubios HRV Standard software to calculate 
HRV.   
 
 3.11 Statistical Analysis 
IBM SPSS Statistics 25 was used for statistical analysis. 
The total number of blood pressure reducing agents each participant was prescribed 
was computed and included alpha-receptor blocking agents, angiotensin-converting 
enzyme inhibitors, angiotensin II receptor blockers, beta-receptor blocking agents, 
calcium channel blockers, diuretics, nitrates, nicorandil and levodopa. Data were non-
parametric. The median and interquartile range (IQR) of the number of drugs 
prescribed was calculated. 
The total number of blood pressure raising agents each participant was prescribed was 
computed and included mirabegron and midodrine. 
Frailty Index was categorised into an ordinal variable with a FI of ≤0.08 classified as 
non-frail, ≥0.25 was classified as frail. All other scores were classified as pre-frail. 
Kruskal-Wallis H test was used to compare frailty groups in the delirium and control 
group. 
Fisher’s Exact test was used to compare the delirium and control groups with regard 
to the proportion of males and females, the proportion of participants with cognitive 
impairment, admission diagnosis, medical history and prescribed medications. A chi-
squared test was not carried out as the assumptions of the test were violated (expected 






In order to eliminate the effect of pre-existing cognitive impairment results were 
analysed for all participants and a second set of analysis was performed using only 
participants without pre-existing cognitive impairment. The results of participants 
with hyperactive and hypoactive delirium were also compared. 
 
A significance level of p≤0.05 was set for all statistical tests. 
 
HUT Statistical Analysis 
Kruskal-Wallis test was used to assess the proportion of participants within each group 
that had orthostatic hypotension and orthostatic hypertension. Changes in systolic 
blood pressure during tilting were correlated to DRS-R98 severity (Spearman’s rho) 
and total score (Pearson’s correlation coefficient). A partial correlation was used to 
adjust for variables that were unequally distributed between the two groups.  
Binary logistic regression was performed to assess the impact that a diagnosis of 
orthostatic hypotension or orthostatic hypertension would have on the likelihood of a 
participant being in the delirium group. Frailty status and a diagnosis of pre-existing 
cognitive impairment were also included in the model. Odds ratios and 95% 
confidence intervals (CI) were calculated. 
BRS Statistical Analysis 
BEI was correlated to DRS-R98 severity and total score. During calculations involving 
the whole group DRS-R98 severity score and erect total BEI used Spearman rho as 
this variable was non-parametric. Other variables were normally distributed and 






Independent samples t-test was used to compare means in normally distributed data. 
Mann-Whitney U test was used to compare medians in non-parametric data. Fisher’s 
Exact test was used to compare nominal variables. Kruskal-Wallis test was used to 
compare nominal to ordinal variables.  
Mean BEI was also calculated for confounding variables. 
 
Blood Pressure Variability Statistical Analysis 
Mann-Whitney U test was used to compare median ARV in the whole group as data 
was non-parametric. Independent samples t-test was used to compare mean ARV in 
the subgroup without pre-existing cognitive impairment, as this data was normally 
distributed. A two–way between group analysis of variance was carried out to explore 
the relationship between delirium, hypertension and ARV.  
Diurnal Blood Pressure Variability Statistical Analysis 
Kruskal-Wallis test was used to compare dipping status between the two groups.  
Heart Rate Variability Statistical Analysis 
SDNN, RMSSD, low frequency HRV and high frequency HRV data were non-
parametric variables and the Mann-Whitney U test was used to compare medians 
between the two groups. 
 
3.12 Amendments to the Original Protocol 
Follow-up autonomic function testing was initially planned to take place six weeks 
following the delirium assessment. After initial recruitment it became apparent that it 






hospital admissions, prolonged recovery times, recurrent illnesses and the 
availability of testing equipment. Autonomic function testing therefore took place at 
a time when the participant was free of an acute illness that could impact on the 
results.  
 
Ethical approval was also received to look for differences in levels of sarcopenia 
between the delirious and control group. This aspect of follow-up testing was not 

















4.0 Prologue to Chapter 
Chapter 4 contains the results of the study. A description of the participants initially 
recruited to the study is first presented. This is followed by an outline of participants 
who did not complete follow up. The results of Head-Up Tilt testing, baroreceptor 
sensitivity, 24-hour blood pressure variability, diurnal blood pressure variability and 
24-hour heart rate variability are then presented separately.  
 
4.1 Initial Participants Recruited 
64 participants were recruited to the study and completed the initial cognitive 
assessments. 51.6% (33) met the diagnostic criteria for delirium.  
25 participants did not attend follow-up. 30.3% (10) of the delirium group were non-
attenders compared to 48.4% (15) of the control group, p=0.14. The reasons for non-
attendance at follow-up are shown in Figure 8. 
When those that attended follow-up were compared to those that did not attend there 
was no difference in age (mean 80.38 years, SD 6.41 vs mean 80.04 years, SD 7.26 
respectively, p=0.84). Females accounted for 44% (11) of non-attenders and 48.7% 
(19) of attenders, p=0.71. A similar proportion of attenders and non-attenders had pre-
existing cognitive impairment (41% vs 48%, p=0.58). 56% of non-attenders were frail. 
A similar proportion of those who attended follow-up were frail (51.3%, p=0.39).  
Those who did not attend follow-up had a higher illness severity score, as measured 
by the APACHE-II with a median score of score of 8.5 (IQR 6) in those who attended 












4.2 Head-Up Tilt Test Results 
4.2.1 Participant Characteristics 
29 patients completed Head-Up Tilt (HUT) testing. 58.6% (17) of these had a 
diagnosis of delirium made by DSM-IV criteria. The mean age was 80.88 years (SD 
5.41) in those with delirium and 80.75 years (SD 7.39) in those without delirium (p= 
0.96). Females accounted for 47.1% (8) of the delirium group and 58.3% (7) of the 
control group (p=0.69).  
17.65% (3) of the delirious group had a pre-existing diagnosis of dementia. An 






existing undiagnosed cognitive impairment.  In the control group, no participant had 
a known diagnosis of dementia and 50% (6) had a positive AD8 questionnaire. 
Therefore, a total of 23.5% (4) participants in the delirium group and 50% (6) of the 
control group were classified has having pre-existing cognitive impairment (p=0.24). 
Delirious participants had a higher median Frailty Index than the control group 
(median FI=0.3, IQR=0.12 vs median FI=0.24, IQR=0.08, p=0.01). 70.6% (12) of the 
delirium group and 25% (3) of the control group were classified as being frail 
(p=0.02). The remainder of both groups were pre-frail. There was no robust participant 
in either group.  
Further patient characteristics are shown in Table 4 while Table 5 displays admission 
diagnosis. Medication use can be found in Table 6. The diagnoses precipitating 
admission and co-morbidities were well-matched across the delirium and control 







Table 4: Head-Up Tilt Test-Patient Characteristics 
 No Delirium Delirium p value 
Number  12 17  
Median Charlson 







Median Barthel Index 
(IQR)          
95 (IQR 14) 90 (IQR 6) 0.52 
Mean APACHE II (SD) 8.57 (3.74)  10.89 (3.66) 0.23 
Previous OH 25% (3) 17.7% (3) 0.69 
Hypertension 50% (6) 47.1% (8) 1 
Ischaemic Heart Disease 16.7% (2) 35.3% (6) 0.41 
Atrial Fibrillation 33.3% (4) 41.2% (7) 0.72 
Previous Stroke 0% (0) 11.8% (2) 0.49 
Diabetes 16.7% (2) 23.5% (4) 1 
History of Depression 8.3% (1) 0% (0) 0.41 
COPD 0% (0) 35.3% (6) 0.02 
CCF 25% (3) 47% (8) 0.27 
Non-Smoker 75% ( (9) 58.8% (10) 0.4 
OH=Orthostatic Hypotension, COPD=Chronic Obstructive Pulmonary Disease, CCF=Congestive Cardiac Failure 
Table 5: Head-Up Tilt Test-Admission Diagnosis 
Admission Diagnosis No Delirium Delirium p value 
Acute Kidney Injury 8.3% (1) 17.6% (3) 0.62 
Acute Liver Injury 8.3% (1) 0% (0) 0.41 
Arrhythmia 0% (0) 6.7% (1) 1 
Anaemia 0% (0) 11.8% (2) 0.49 




33.3% (4) 58.8% (10) 0.33 
Cardiac Failure 8.3% (1) 35.3% (6) 0.19 
Fall/Syncope 41.7% (5) 29.4% (5) 0.64 
Hyponatraemia  8.3% (1) 6.7% (1) 1 
Symptomatic Goitre 8.3% (1) 0% (0) 0.41 
Pulmonary Embolus 16.7% (2) 0% (0) 0.13 
Hip Fracture 0% (0) 11.8% (2) 0.5 
Urinary Retention 8.3% (1) 0% (0) 0.41 
Total Knee 
Replacement 
8.3% (1) 0% (0) 0.41 
Non-cardiac chest pain 0% (0) 6.7% (1) 1 
Table 5 displays the number of participants in each group that had the listed admission diagnosis. Patients may have had more 






Table 6: Head-Up Tilt Test-Medications on Admission 
Medication No Delirium Delirium p value 
Alpha-blocker 0% (0) 17.6% (3) 0.23 
Anticholinergic 8.3% (1) 0% (0) 0.41 




8.3% (1) 17.6% (3) 0.62 
Angiotension Receptor 
Blocker (ARB) 




41.7% (5) 29.4% (5) 0.64 
Diuretic* 33.3% (4) 76.5% (13) 0.03 
Calcium Channel 
Blocker 
33.3% (4) 35.3% (6) 1 
Donepezil 0% (0) 6.7% (1) 1 
Memantine 0% (0) 11.8% (2) 0.5 
Midodrine 25% (3) 11.8% (2) 0.62 
Mirabegron 8.3% (1) 0% (0) 0.41 
Nitrate 0% (0) 17.6% (3) 0.25 
Median number of 
blood pressure 
lowering agents per 
person 
2, range 0-3, IQR 3 2, range 1-5, IQR 
1.5 
0.2 
Median number of 
blood pressure raising 
agents per person 
0, range 0-1, IQR 1 0, range 0-1, IQR  0.13 
*Includes the use of diuretics for the treatment of heart failure, liver failure or hypertension 
4.2.2 HUT Results 
The delirium group had a median decrease of 1mmHg (IQR 38.5) in systolic blood 
pressure and a median increase of 9mmHg (IQR 28) in diastolic blood pressure. The 
control group had a median decrease of 17.5mmHg (IQR 20.75) in systolic blood 
pressure and a median increase of 0.5mmHg (IQR 10) in diastolic blood pressure, 






As DRS-R98 severity scores increased systolic blood pressure change during HUT 
also increased (rs= 0.42, p=0.03). A similar pattern was present for total DRS-R98 
scores (rs =0.4, p=0.03).  
A partial correlation was carried out to control for variables that were unequally 
distributed between the two groups (cognitive impairment, Chronic Obstructive 
Pulmonary Disease (COPD), frailty and diuretic use). DRS-R98 severity scores 
maintained a similar pattern (rs= 0.46, p=0.02). There was a non-significant 
correlation between DRS-R98 total score and systolic blood pressure change, rs= 0.37, 
p=0.07. 
35.3% (6) of patients in the delirium group had orthostatic hypotension compared to 
50% (6) of the control group. 47.1% (8) of the delirium group had orthostatic 
hypertension compared to 8.3% (1) of the control group (p=0.14).  
When a subgroup analysis of participants (19) without cognitive impairment was 
carried out, the rate of orthostatic hypertension was 53.8% (7) in the delirium group 
and no patients in the control group had orthostatic hypertension (p=0.03). This is 
shown in Figure 9. 
4.2.3 Confounding Variables 
Rates of orthostatic hypotension did not vary with gender. 53.3% (8) of females and 
28.6% (4) of males had orthostatic hypotension. 20% (3) of females and 42.9% (6) of 
males had orthostatic hypertension while the remainder had a normal test, p=0.14.  
There was no relationship between the presence of frailty, COPD or diuretic use and 






Figure 9: Orthostatic Hypertension is more common in the Delirium Group 
                                       
Figure 9 shows the proportion of participants without pre-existing cognitive impairment in the delirium and control group who 
had orthostatic hypotension and orthostatic hypertension. 




Table 7: Head-Up Tilt Test-Confounding Variables 











No diuretic use 
44.4% (4) 
55.6% (5) 














Table 7 shows the proportion of participants with OHTN, OH and normal tilt test who had frailty, COPD, CCF and used diuretics. 
COPD=Chronic Obstructive Pulmonary Disease, OH=Orthostatic Hypotension, OHTN=Orthostatic Hypertension, 
















Binary logistic regression was performed to assess the impact that orthostatic 
hypertension, orthostatic hypotension, frailty and pre-existing cognitive impairment 
had on a diagnosis of delirium. The full model was statistically significant, χ2 (4, 
N=29)=15.22, p<0.01. The model explained between 40.8% (Cox and Snell R square) 
and 55% (Nagelkerke R squared) of the variance in delirium status and correctly 
classified 75.9% of cases. Both orthostatic hypertension and frailty made a unique 
statistically significant contribution to the model. The odds ratio of those with 
orthostatic hypertension having delirium was 34.06 (95% CI 1.31-893.18, p=0.03). 
The odds ratio of those with frailty having delirium was 15.28 (95% CI 1.6-147.75, 
p=0.02). 
As it was felt likely that pre-existing cognitive impairment would have a significant 
impact on the development of delirium a model containing just cognitive impairment 
was carried out. This model was not significant, χ2 (2, N=29)=2.18, p=0.14. The model 
was also run to assess the impact of pre-existing cognitive impairment and frailty had 
on a diagnosis of delirium. The overall model was significant, χ2 (3, N=29)=8.63, 
p=0.01, but only frailty contributed to the model. The odds ratio of those with pre-
existing cognitive impairment having delirium was 0.23 (95% CI 0.04-1.52, p=0.23) 
The model was rerun using just the variables that added a significant contribution-
orthostatic hypertension and frailty. The full model was statistically significant, χ2 (3, 
N=29)=12.32, p<0.01. The model explained between 34.6% (Cox and Snell R square) 
and 46.6% (Nagelkerke R squared) of the variance in delirium status and correctly 
classified 79.3% of cases. Both orthostatic hypertension and frailty made a unique 
statistically significant contribution to the model. The odds ratio of those with 
orthostatic hypertension having delirium was 15.53 (95% CI 1.2-200.19, p=0.04). The 







4.2.4 Impact of Delirium Subtype on HUT results 
Five participants had hyperactive delirium and six had hypoactive delirium. 
Participants with hyperactive delirium had a mean increase in systolic blood pressure 
on tilting of 9.2mmHg (SD 12.6). Hypoactive participants had a mean decrease in 
systolic blood pressure of 10.2mmHg (SD 20.3), p=0.1. One participant in each group 
had pre-existing cognitive impairment. When they were excluded the hyperactive 
group had a mean increase in systolic blood pressure of 13.3mmHg (SD 10) and the 
hypoactive group had a mean decrease of 8.6 (SD 22.3), p=0.11. 
 
Participants with hyperactive delirium had a median increase in diastolic blood 
pressure on tilting of 20mmHg (IQR 20). Hypoactive participants had a median 
increase in DBP of 0.5mmHg (SD 23), p=0.14. When the two participants with pre-
existing cognitive impairment were excluded the hyperactive group had a mean 
increase in diastolic blood pressure of 19.8mmHg (SD 3.4) and the hypoactive group 









4.3 Baroreflex Sensitivity Results 
4.3.1 Participant Characteristics 
25 patients completed Baroreflex Sensitivity (BRS) testing. 56% (14) of these had a 
diagnosis of delirium made by DSM-IV criteria. The mean age was 81.36 years (SD 
5.76) in those with delirium and 79.82 years (SD 8.16) in those without delirium, t=-
0.55, p= 0.59. Females accounted for 50% (7) of the delirium group and 63.6% (7) of 
the control group, p=0.69.  
7.7% (1) of the delirious group had a pre-existing diagnosis of dementia. An additional 
7.7% (1) had a positive AD8 informant questionnaire, suggesting pre-existing 
cognitive impairment. In the control group, no participant had a known diagnosis of 
dementia and 54.5% (6) had a positive AD8 questionnaire. Therefore, a total of 14.3% 
(2) participants in the delirium group and 54.5% (6) of the control group were 
classified as having pre-existing cognitive impairment (p=0.81). 
Delirious participants had a median Frailty Index of 0.27 (SD 0.06). The control group 
had a median Frailty Index of 0.22 (SD 0.07), p= 0.06. 64.3% (9) of the delirium group 
and 27.3% (3) of the control group were classified as being frail (p=0.07). The 
remainder of both groups were pre-frail.  
Further patient characteristics are shown in Table 8 while Table 9 displays admission 









Table 8: Patient Characteristics for Baroreceptor Sensitivity Study 
 No Delirium Delirium p value 










Median Barthel Index 
(IQR)          
92 (15) 92 (7) 0.57 
Mean APACHE II (SD) 8.38 (3.5)  11 (3.89) 0.18 
Hypertension 54.5% (6) 42.3% (6) 0.7 
Ischaemic Heart 
Disease 
18.2% (2) 35.7% (5) 0.41 
Atrial Fibrillation 27.3% (3) 35.7% (5) 1 
Previous Stroke 0% (0) 14.3% (2) 0.49 
COPD 0% (0) 35.7% (5) 0.05 
Diabetes 18.2% (2) 14.3% (2) 1 
History of Depression 18.2% (2) 0% (0) 0.18 
COPD=Chonic Obstructive Airway Disease 
 
 
Table 9: Admission Diagnosis for Baroreceptor Sensitivity Study 
Admission Diagnosis No Delirium Delirium p value 
Acute Kidney Injury 9.1% (1) 21.4% (3) 0.6 
Acute Liver Injury 9.1% (1) 0% (0) 0.4 
Arrhythmia 0% (0) 7.1% (1) 1 
Anaemia 0% (0) 14.3% (2) 0.49 




18.2% (2) 64.3% (9) 0.04 
Cardiac Failure 0% (0) 42.3% (6) 0.02 
Fall/Syncope 45.5% (5) 21.4% (3) 0.39 
Hyponatraemia  18.2% (2) 7.1% (1) 0.57 
Symptomatic Goitre 9.1% (1) 0% (0) 0.44 
Pulmonary Embolus 9.1% (1) 0% (0) 0.44 
Hip Fracture 0% (0) 7.1% (1) 1 
Non-cardiac chest 
pain 
0% (0) 7.1% (1) 1 
Table 9 displays the number of participants in each group that had the listed admission diagnosis. Patients may have had more 






Table 10: Medications on Admission in Baroreceptor Sensitivity Study 
Medication No Delirium Delirium p value 
Alpha-blocker 0% (0) 14.3% (2) 0.49 
Anticholinergic 9.1% (1)  0% (0) 0.42 












45.5% (5) 28.6% (4) 0.4 
Diuretic 27.3% (3) 85.7% (12)  0.02 
Calcium Channel 
Blocker 
36.4% (4) 35.7% (5) 1 
Digoxin 9.1% (1) 14.3% (2) 1 
Donepezil 0% (0) 7.1% (1) 1 
Memantine 0% (0) 0% (0)  
Midodrine 27.3% (3) 7.1% (1) 0.27 
Mirabegron 0% (0) 0% (0)  
Nitrate 0% (0) 21.4% (3) 0.24 
Median number of 
blood pressure 
lowering agents per 
person (IQR) 





Median number of 
blood pressure raising 
agents per person 
0 range 0-1, 
IQR=1 




4.3.2 Baroreflex Sensitivity Results 
BEI: All Participants 
Mean BEI during the supine phase was 37.1% (SD 18.47) in the delirium group and 
58.57% (SD 29.56) in the control group, p=0.06. During the tilting phase median BEI 







DRS-R98 severity score was negatively correlated to supine BEI, r2=-0.44 p=0.05. 
The correlation between DRS-R98 total score and supine BEI was r=-0.43 p=0.05. 
There was no linear relationship between DRS-R98 scores and BEI during the tilting 
phase. 
BEI: Participants with no Pre-existing Cognitive Impairment 
When participants without pre-existing cognitive impairment where looked at in 
isolation mean supine BEI was 37.06% (SD 19.65) in the delirium group and 67.59% 
(SD 26.26) in the control group, p=0.03. During the tilting phase median BEI was 
19.3% (IQR 47.14) in those with delirium and 50.78% (IQR 37.85) in those without 
delirium (p=0.14).  
DRS-R98 total score was negatively correlated to supine BEI, r=-0.56 p=0.04. The 
correlation between DRS-R98 severity score and supine BEI was r=-0.5 p=0.07. There 
was no linear relationship between DRS-R98 scores and BEI during the tilting phase. 
BEI-Up: All Participants 
Mean supine BEI-Up was 60.63% (SD 34.28%) and 66.97% (SD 34.55%) in the 
delirium and control group respectively, p=0.76. Mean erect BEI-Up was 28.93% (SD 
20.03) in the delirious participants compared to 43.73% (SD 22.59) in the non-
delirious group, p=0.11). 
DRS-R98 total score was negatively correlated to supine BEI, r=-0.56 p=0.04. 
BEI-Up: Participants with no Pre-existing Cognitive Impairment 
When participants without pre-existing cognitive impairment where looked at in 
isolation mean supine BEI-Up was 60.63% (SD 34.28) in the delirium group and 






was 36.87% (SD 22.26) in those with delirium and 56.03 (SD 23.04) in those without 
delirium, p=0.05. 
During tilting BEI-Up was non-significantly correlated to DRS-R98 total score, r=-
0.49, p=0.06. 
BEI-Down: All Participants 
Mean supine BEI-Down was 40.01% (SD 16.65) and 65.91% (SD 22.8) in the delirium 
and control groups respectively, p=0.04. During tilting Mean BEI-Down was 41% (SD 
26.81) and 50.8% (SD 23.47) in the delirium and control groups respectively, p= 0.36. 
BEI-Down: Participants with no Pre-existing Cognitive Impairment 
When participants without pre-existing cognitive impairment where looked at in 
isolation mean supine BEI-Down was 40.97% (SD 17.74) in the delirium group and 
65.91% (SD 22.8) in the control group, p=0.04. During the tilting phase mean BEI 
was 38.71% (SD 25.97) in those with delirium and 61.25% (SD 26.05) in those 
without delirium, p=0.21. 
Supine BEI-Down was non-significantly correlated to DRS-R98 total score, r=-0.5, 
p=0.08. 
A summary of the BEI scores in participants without pre-existing cognitive 







Figure 10: Baroreflex Effectiveness Index in Participants with Normal Baseline 
Cognition
 
Figure 10 compares Baroreflex Effectiveness Index in the delirium and control groups during the tilting phase of the Head-Up 
Tilt test. BEU-Up is the proportion of increases in blood pressure followed by an appropriate decreased in heart rate. BEI-
Down is the proportion of decreases in blood pressure followed by an appropriate increase in heart rate. 
 
4.3.3 Impact of Delirium Subtype 
A comparison of BEI in participants with hyperactive and hypoactive delirium is 














Mean Supine BEI 
(SD) 
35.31% (16.62) 29.56% (19.36) 0.67 
Median Erect BEI 
(IQR) 
28.26% (43.27) 25.5% (30.62) 0.25 
Mean Supine BEI-Up 
(SD) 
64.3% (35.47) 27.09 (20.63) 0.25 
Mean Erect BEI-Up 
(SD) 
35.39% (17.48) 21.46 (26.73) 0.38 
Mean Supine BEI-
Down (SD) 
36.06% (12.91) 38.15 (22.33) 0.95 
Mean Erect BEI-
Down (SD) 
53.31% (33.84) 34.33% (21.34) 0.37 
 
 
4.3.4 Confounding Factors and BEI 
Mean BEI was calculated for the variables that were found to be unequally distributed 









Table 12: Confounding Variables for Baroreceptor Sensitivity Study 


































































































































































































Table 12 shows a comparison of BEI between those with pre-frailty and frailty, diuretic and non-diuretic use and participants 
with and without COPD (Chronic Obstructive Pulmonary Disease), CCF (Congestive Cardiac Failure) and a diagnosis of 







4.4 Blood Pressure Variability 
4.4.1 Patient Characteristics 
35 patients completed blood pressure variability (BPV) testing. 60% (21) of these had 
a diagnosis of delirium made by DSM-IV criteria. The mean age was 81.3 years (SD 
6.1) in those with delirium and 80 years (SD 7.3) in those without delirium (p=0.49). 
Females accounted for 42.9% (9) of the delirium group and 71.4% (10) of the control 
group (p=0.1).  
9.5% (2) of the delirious group had a pre-existing diagnosis of dementia. An additional 
23.81% (5) had a positive AD8 informant questionnaire. In the control group, 1 
participant (7.1%) had a known diagnosis of dementia and 42.86% (6) had a positive 
AD8 questionnaire. Therefore, a total of 33.3% (7) participants in the delirium group 
and 50% (7) of the control group were classified as having pre-existing cognitive 
impairment (p=0.32). 
Delirious participants had a median Frailty Index of 0.29 (IQR 0.08). The control 
group had a median Frailty Index of 0.21 (IQR 0.07), p= 0.03. 71.4% (15) of the 
delirium group and 21.4% (3) of the control group were classified as being frail 
(p<0.01). The remainder of both groups were pre-frail.  
24-hour mean systolic blood pressure was 129.95mmHg (SD 17.68) in the delirium 
group and 139.36mmHg (SD 22.39) in the control group (p=0.18). Mean 24-hour 
diastolic blood pressure was 72.5mmHg (SD 11.43) in the delirium group and 
74mmHg (SD 10.13) in the control group (p=0.7). 
Further patient characteristics are shown in Table 13 while Table 14 displays 






Table 13: Blood Pressure Variability-Patient Characteristics 
 No Delirium Delirium p value 
Number  14 21  
Median Charlson 
Comorbidity Index (IQR) 




Mean Barthel Index (SD)          91.31 (8.14) 92.38 (5.57) 0.68 
Mean APACHE II (SD) 8.38 (3.5)  10.89 (3.66) 0.17 
Hypertension 61.5% (8) 57.1% (12) 1 
Ischaemic Heart Disease 14.3% (2) 38.1% (8) 0.25 
Atrial Fibrillation 21.4% (3) 33.3% (7) 0.7 
CCF 7.1% (1) 23.8% (5) 0.37 
Previous Stroke 0% (0) 14.3% (3) 0.27 
Parkinson’s Disease 7.1% (1) 0% (0) 0.4 
COPD 0% (0) 28.6% (6) 0.06 
CKD 0% (0) 4.8% (1) 1 
Diabetes 11.8% (2) 14.3% (3) 1 
History of Depression 11.8% (2) 0% (0) 0.13 
 
 
Table 14: Blood Pressure Variability-Admission Diagnosis 
Admission Diagnosis No Delirium Delirium p value 
Acute Kidney Injury 7.1% (1) 14.3% (3) 0.64 
Acute Liver Injury 7.1% (1) 0% (0) 0.4 
Arrhythmia 0% (0) 9.5% (2) 0.51 
Anaemia 0% (0) 9.5% (2) 0.51 




28.6% (4) 66.7% (14) 0.09 
Cardiac Failure 0% (0) 33.3% (7) 0.03 
Fall/Syncope 35.7% (5) 33.3% (7) 1 
Hyponatraemia  11.8% (2) 9.5% (2) 1 
Symptomatic Goitre 7.1% (1) 0% (0) 0.4 
Pulmonary Embolus 7.1% (1) 0% (0) 0.4 
Hip Fracture 0% (0) 9.5% (2) 0.51 
Non-cardiac chest pain 0% (0) 4.8% (1) 1 
Urinary Retention 7.1% (1) 0% (0) 0.4 
Table 14 displays the number of participants in each group that had the listed admission diagnosis. Patients may have had more 







Table 15: Blood Pressure Variability-Medications on Admission 
Medication No Delirium Delirium p value 
Alpha-blocker 0% (0) 9.5% (2) 0.51 
Anticholinergic 7.1% (1) 0% (0) 0.38 




11.8% (2) 9.5% (2) 0.63 
Angiotension Receptor 
Blocker (ARB) 




35.7% (5) 23.8% (5) 0.45 
Diuretic 21.4% (3) 80.1% (17) 0.01 
Calcium Channel 
Blocker 
28.6% (4) 28.6% (6) 1 
Donepezil 7.1% (1) 4.8% (1) 1 
Memantine 0% (0) 4.8% (1) 1 
Midodrine 7.1% (1) 0% (0) 0.65 
Mirabegron 7.1% (1) 0% (0) 0.38 
Nicorandil 0% (0) 4.8% (1) 1 
Nitrate 0% (0) 14.3% (3) 0.27 
Median number of 
blood pressure lowering 
agents per person 
2, range 0-3, IQR 
2.5 
2, range 0-5, IQR 
1.5 
0.3 
Median number of 
blood pressure raising 
agents per person 




4.4.2 BPV Results 
All Participants 
Median ARV was 12.71 (IQR 5.58) in the control group and 9.93 (IQR 4.85) in the 
delirium group (p=0.12).   
Within the delirious group the mean ARV in those with hyperactive delirium was 






Participants Without Cognitive Impairment 
In those without pre-existing cognitive impairment mean ARV was 13.81 (SD 5.98) 
in the control group and 9.69 (SD 2.75) in the delirium group (p=0.05).  
4.4.3 Confounding Variables and BPV 
When other diagnosis and medication use that could impact on BPV were analysed 
only hypertension was found to impact on ARV (Table 16). Participants within the 
hypertensive group who had delirium had a mean ARV of 10.8 (SD 2.2). Those with 
hypertension and no delirium had a mean ARV of 16.3 (SD 6.9), p=0.06. 
A two–way between group analysis of variance was carried out to explore the 
relationship of delirium and hypertension on ARV in participants without pre-existing 
cognitive impairment. The interaction effect between hypertension and delirium was 
not significant, F=0.53, p=0.48. There was a statistically significant main effect for 
delirium, F=5.29, p=0.04, partial eta squared=0.25. The main effect for hypertension 







Table 16: Relationship Between Average Real Variability and Confounding 
Variables 



















































































































4.5 Diurnal Blood Pressure Variability 
4.5.1 Participant Characteristics 
The participants for this part of the study are the same as those who completed BPV 
testing and thus their characteristics can be found in Section 5.4. 
4.5.2 Diurnal Blood Pressure Variability Results  
All Participants 
Within the delirium group, 57.9% (11) of participants were reverse dippers, 26.3% (5) 
were non-dippers, 10.5% (2) had a normal dipping pattern and 5.3% (1) was an 
extreme dipper. 
In the control group 35.7% (5) were reverse dippers, 35.7% (5) were non-dippers, 
14.3% (2) had a normal dipping pattern and 14.3% (2) were extreme dippers. There 
was a non-significant difference between the two groups, p=0.19. 
Participants Without Pre-existing Cognitive Impairment 
Within the delirium group, 58.3% (7) of participants were reverse dippers, 33.3% (4) 
were non-dippers and 8.3% (1) had a normal dipping pattern. No participant was an 
extreme dipper. 
In the control group no participant was a reverse dipper, 57.1% (4) were non-dippers, 
14.3% (1) had a normal dipping pattern and 28.6% (2) were extreme dippers. There 






Figure 11: Blood Pressure Dipping Status in Participants without Pre-existing 
Cognitive Impairment 
                                  
Figure 11 shows the dipping in the delirium group compared to the control group in the subgroup without cognitive impairment 
(N=21). Within the delirium group no participant was an extreme dipper. All participants who were extreme dippers were in the 
control group. 
4.5.3 Confounding Variables 
There was no relationship between dipping status and any of the following variables: 
frailty or pre-frailty (p=0.27), pre-existing cognitive impairment (p=0.58), COPD 
(p=0.5), ischaemic heart disease (p=0.29), hypertension (p=0.41) or diuretic use 
(p=0.85). 
4.5.4 Effect of Delirium Subtype on Dipping Status  
Six participants had hyperactive delirium. 66.7% (4) were reverse dippers. None of 
these had pre-existing cognitive impairment. Of the remaining two participants with 
hyperactive delirium one was a dipper and one was an-extreme dipper. Both of these 



















Four participants had hypoactive delirium. None of these had pre-existing cognitive 
impairment. 50% (2) were reverse dippers, 1 was a non-dipper and 1 was a normal 
dipper. 
No statistically significant relationship between hypoactive and hyperactive delirium 











4.6 Heart Rate Variability 
4.6.1 Patient Characteristics 
26 patients completed Heart Rate Variability (HRV) testing. 65.2% (17) of these had 
a diagnosis of delirium made by DSM-IV criteria. The mean age was 80.2 years (SD 
5.1) in those with delirium and 80.1 years (SD 7.5) in those without delirium (p= 0.85). 
Females accounted for 41.2%% (7) of the delirium group and 77.8% (7) of the control 
group (p=0.1).  
5.9% (1) of the delirious group had a pre-existing diagnosis of dementia. An additional 
17.6% (3) had a positive AD8 informant questionnaire. In the control group, 1 
participant (11.1%) had a known diagnosis of dementia and 44.4% (4) had a positive 
AD8 questionnaire. Therefore, a total of 23.5% (4) participants in the delirium group 
and 55.6% (5) of the control group were classified has having pre-existing cognitive 
impairment (p=0.19). 
Delirious participants had a median Frailty Index of 0.33 (IQR 0.12). The control 
group had a median Frailty Index of 0.24 (IQR 0.12), p=0.01. 70.6% (12) of the 
delirium group and 11.1% (1) of the control group were classified as being frail 
(p=0.01). The remainder of both groups were pre-frail.  
Within the delirium group four participants had hyperactive delirium and seven 
participants had hypoactive delirium. 
Further patient characteristics are shown in Table 17 while Table 18 displays 







Table 17: Heart Rate Variability-Patient Characteristics 
 No Delirium Delirium p value 
Number  9 17  
Mean Charlson 
Comorbidity Index (SD) 




Mean Barthel Index (SD)          92.13 (9.48) 92.46 (5.25) 0.92 
Mean APACHE II (SD) 9 (3.68)  11.38 (3.58) 0.25 
Hypertension 55.6% (5) 55.9% (9) 1 
Ischaemic Heart Disease 22.2% (2) 33.5% (6) 0.67 
CCF 0% (0) 23.5% (4) 0.27 
Previous Stroke 0% (0) 11.8% (2) 1 
COPD 0% (0) 41.2% (7) 0.06 
CKD 0% (0) 5.9% (1) 1 
Diabetes 11.1% (1) 17.6% (3) 1 
History of Depression 11.1% (1) 5.9% (1) 1 
 
 
Table 18: Heart Rate Variability-Admission Diagnosis 
Admission Diagnosis No Delirium Delirium p value 
Acute Kidney Injury 0% (0) 17.6% (3) 0.53 
Acute Liver Injury 11.1% (1) 0% (0) 0.35 
Arrhythmia 0% (0) 11.8% (2) 0.53 
Anaemia 0% (0) 11.8% (2) 0.53 




22.2% (2) 70.6% (12) 0.04 
Cardiac Failure 0% (0) 33.5% (6) 0.06 
Fall/Syncope 33.3% (3) 33.5% (6) 1 
Hyponatraemia  22.2% (2) 11.8% (2) 0.59 
Symptomatic Goitre 11.1% (1) 0% (0) 0.5 
Pulmonary Embolus 11.1% (1) 0% (0) 0.5 
Hip Fracture 0% (0) 5.9% (1) 1 
Table 18 displays the number of participants in each group that had the listed admission diagnosis. Patients may have had more 






Table 19: Heart Rate Variability-Medications on Admission 
Medication No Delirium Delirium p value 
Alpha-blocker 0% (0) 17.6% (3) 0.53 
Anticholinergic 7.1% (1) 0% (0) 0.32 




11.1% (1) 5.9% (1) 1 
Angiotension Receptor 
Blocker (ARB) 




22.2% (2) 23.5% (4) 1 
Diuretic 22.2% (2) 70.6% (12) 0.04 
Calcium Channel 
Blocker 
33.3% (3) 29.4% (5) 1 
Digoxin 0% (0) 5.9% (1) 1 
Donepezil 7.1% (1) 0% (0) 0.35 
Memantine 0% (0) 5.9% (1) 1 
Midodrine 7.1% (1) 5.9% (1) 1 
Nicorandil 0% (0) 5.9% (1) 1 
Nitrate 0% (0) 17.6% (3) 0.53 
 
 
4.6.2 HRV Results 
SDNN 
Median SDNN was 105.59 (IQR 412.02) in the delirium group and 86.6 (IQR 925.91) 
in the control group, p=0.67. When participants with pre-existing cognitive 
impairment were excluded median SDNN was 216.38 (IQR 479.92) in the delirium 
group and 956.12 (IQR 1136.52) in the control group, p=0.14. There was no difference 
between participants with hyperactive (median 90.45, IQR 1216.5) and hypoactive 
(median 216.38, IQR 400.43) delirium, p=0.85. 
RMSSD 
Median RMSSD was 114.9 (IQR 492.42) in the delirium group and 94.1 (IQR 809.82) 






were excluded median RMSSD was 147.22 (IQR 486.27) in the delirium group and 
851.27 (IQR 908.15) in the control group, p=0.5. There was no difference between 
participants with hyperactive (mean 234.78, SD 280.39) and hypoactive (mean 
273.49, SD 226.84) delirium, p=0.81. 
SDNN and RMSSD results displayed shown in Figure 12. 
 
Figure 12: Heart Rate Variability in Participants with Normal Baseline 
Cognition 
 








Low Frequency HRV (LFHRV) 
Median LFHRV was 1,560.5 Hz (IQR 122,667) in the delirium group and 18,746 Hz 
(IQR 978,291) in the control group, p=0.61. When participants with pre-existing 
cognitive impairment were excluded median LFHRV was 23,352 Hz (IQR 122,270.5) 
in the delirium group and 978,560 Hz (IQR 1,869,835.5) in the control group, p=0.06. 
There was no difference between participants with hyperactive (median 1,287.75 Hz, 
IQR 894,734.88) and hypoactive (median 23,352Hz, IQR 100,906) delirium, p=0.85. 
High Frequency HRV (HFHRV) 
Median HFHRV was 5,804.5 (IQR 399,903.5) in the delirium group and 2,906Hz 
(IQR 3,067,654.5) in the control group, p=0.65. When participants with pre-existing 
cognitive impairment were excluded median HFHRV was 21,820Hz (IQR 
1,100,157.5) in the delirium group and 3,068,000Hz (IQR 5,066,970.5) in the control 
group, p=0.09. There was no difference between participants with hyperactive 
(median 4,309.25Hz, IQR 3,003,231.61) and hypoactive (median 21,820Hz, IQR 
1,732,540) delirium, p=0.85. 
LF/HF 
The median LF/HF ratio was 0.47 (IQR 0.53) in the delirium group and 0.74 (IQR 
2.46) in the control group (p=0.5). When participants with pre-existing cognitive 
impairment were excluded the median LF/HF ratio was 0.37 (IQR 0.46) in the delirium 
group and 0.35 (IQR 4.62) in the control group (p=0.82). There was no difference 
between participants with hyperactive (median 0.33, IQR 0.62) and hypoactive 
(median 0.63, IQR 0.31) delirium, p=0.58.  
4.6.3 Confounding Variables 








Table 20: Heart Rate Variability and Confounding Variables 






















































































5.0 Prologue to Chapter 
Chapter 5 begins by summarising the findings of this study. I then discuss possible 
mechanisms to explain the results, directions for future study and the strengths and 
weaknesses of the study. 
5.1 Summary and Interpretation of Results 
5.1.1 Head-Up Tilt Test 
The results of this study show that participants with recent delirium have higher rates 
of orthostatic hypertension and less orthostatic hypotension than participants without 
delirium. This was most pronounced when participants with pre-existing cognitive 
impairment were excluded and the delirium group were compared to controls with 
baseline and current normal cognition.  
Participants with orthostatic hypertension had an odds ratio of 34 of being in the 
delirium group, even when frailty and pre-existing cognitive impairment were 
included in the model. The odds ratio was associated with a wide confidence interval. 
This reflects the small sample size. Due to the sample size more factors were not 
included in the analysis. 
Blood pressure changes during HUT were correlated with delirium severity based on 
DRS-R98 scores, with participants with more severe delirium having greater increases 
in blood pressure. This indicates a possible exposure-response relationship. 
Diuretic use was higher in the delirium groups compared to the control group. There 
was no statistically significant difference in other antihypertensive use. There was 
however a trend towards higher use of alpha-blockers and nitrates in the delirium 






Milazzo et al. 2012), they would not have contributed to the higher rate of orthostatic 
hypertension in the delirium group.  
Part of the hypothesis of this study was that the delirium group would have higher 
rates of orthostatic hypotension and may be predisposed to cognitive changes due to 
decreases in cerebral perfusion on standing. The results of the study indicate that the 
reverse is true, delirium is associated with increases in blood pressure on standing. 
This does however still support the main hypothesis-that delirium is associated with 
abnormal autonomic function. Previous studies have shown that orthostatic 
hypertension is associated with autonomic impairment, reduced baroreceptor 
sensitivity and excess sympathetic activity (Chhabra and Spodick 2013). Excessive 
sympathetic activity is associated with cerebral vasoconstriction (Tameem and 
Krovvidi 2013) which supports the hypothesis that delirium may be assoicated with 
reduced cerebral perfusion. 
In summary, the results of the HUT part of this study suggest that participants with 
delirium may have abnormal autonomic function and in particular may have excess 
sympathetic activity. 
5.1.2 Baroreflex Sensitivity 
This study identified reduced baroreceptor function, as measured by Baroreflex 
Effectiveness Index (BEI), in participants with delirium compared to controls. This is 
particularly true when the impact of pre-existing cognitive impairment is excluded. 
BEI also correlates with delirium severity with participants with more severe delirium 
having reduced BEI.  
Supine BEI was lower in participants with delirium and no pre-existing cognitive 






reductions in blood pressure that are followed by an appropriate increase in heart rate.  
There was no difference identified in BEI-Up. The conclusion in my study population 
is that reductions in blood pressure are not followed by a corrective increase in heart 
rate in the delirium group compared to the control group. This implies either an 
impairment of sympathetic nervous system activation or excess parasympathetic 
activity. 
During the tilting phase of the test there was a non-significant difference in BEI 
between the groups but a difference was detected in BEI-Up, with delirious 
participants having lower values. There was no difference in BEI-Down. Therefore, 
during tilting increases in blood pressure were not followed by an appropriate 
corrective reduction in heart rate. This implies either excess sympathetic activity or a 
failure of parasympathetic activation.  
The results of the supine BEI and the BEI measured during tilting are not congruent. 
The small sample size may have impacted on the results.  
5.1.3 Nocturnal Blood Pressure Dipping Status 
This study also identified that participants with delirium are more likely to have a 
reverse nocturnal dipping pattern of blood pressure compared to controls with no pre-
existing cognitive impairment. Both the delirium and control groups had similar rates 
of diagnosed hypertension, similar use of antihypertensives and similar 24-hour mean 
blood pressure. The results suggest that delirium may be associated with abnormally 
high nocturnal sympathetic nervous system activity.  
5.1.4 24-Hour Blood Pressure Variability 
This study found that among participants with no pre-existing cognitive impairment, 






was lower in the delirium compared to the control group. This difference was largely 
driven by a lower ARV in hypoactive delirious participants, suggesting that 
participants with hypoactive, but not hyperactive delirium, may have lower 
sympathetic nervous system activity. Patients with hypoactive and hyperactive 
delirium may have different autonomic nervous system profiles and should be 
investigated separately in future studies. 
5.1.5 24-Hour Heart Rate Variability 
This study identified no difference in 24-hour Heart Rate Variability when comparing 
the delirium and control groups, regardless of pre-existing cognitive status. There was 
however a trend towards delirious participants having lower HRV and in particular 
hypoactive participants tended to have higher HFHRV (reflecting higher 
parasympathetic activity) and hyperactive participants had higher LFHRV (reflecting 
higher sympathetic activity).  
The lack of a statistically significant finding is similar to the results found in a previous 
study of short term heart rate variability in an ICU setting (Zaal et al. 2014). The 
inability to detect a difference between the two groups may relate to the small sample 
size used in both studies.  
A post hoc test was carried out to determine the effect size for LFHRV (r=0.1) and 
HFHRV (r=0.09), indicating a small effect size. When the effect size for participations 
without pre-existing cognitive impairment was calculated there was found to be a 
moderate effect size (r=0.38 for HFHRV and r=0.38 for LFHRV). 
Following the commencement of this work, Oh et al published the findings of their 






be used to predict the development of delirium (Oh et al. 2018). The difference in 
findings between these studies may relate to the larger sample size used by Oh et al. 
5.1.6 Impact of Delirium Subtype 
During tilt testing the hyperactive participants had an overall increase in both systolic 
and diastolic blood pressure while hypoactive participants had an overall reduction in 
blood pressure. The difference was only statistically significant for diastolic changes 
in participants with no pre-existing cognitive impairment. This may reflect higher 
sympathetic activity in the hyperactive group. 
Supine BEI-Up was non-statistically higher in hyperactive compared to hypoactive 
participants. This may imply that hyperactivity is associated with higher sympathetic 
or lower parasympathetic activity than hypoactivity. 
Excluding those participants with pre-existing cognitive impairment, all of the 
hyperactive participants displayed a reverse nocturnal blood pressure dipping pattern. 
This compares to half of hypoactive participants displaying the same pattern. Again, 
this may suggest higher sympathetic activity in hyperactive participants. 
24-hour blood pressure variability was lower in hypoactive compared to hyperactive 
participants. This suggests lower sympathetic activity in the hypoactive group. 
Although there was no statistically significant difference detected between the 
hyperactive and hypoactive groups when looking at HRV there was a trend towards 
higher parasympathetic components (HFHRV) in the hypoactive group. 
The validity of these comparisons is greatly limited by the very small sample size of 






that hyperactive and hypoactive delirium may differ in autonomic abnormalities with 
the difference in clinical presentation reflecting alterations in sympathetic and 
parasympathetic balance.  
5.1.7 Combining the Results 
Overall the results suggest that delirious participants have altered autonomic nervous 
system function when compared to participants with normal cognition. Whether these 
alterations reflect abnormalities in sympathetic or parasympathetic function are not 
consistent across the tests. The general trend of my research would suggest a pattern 
of sympathetic over-activity in hyperactive delirium patients. The severity of the 
autonomic changes also correlated with the severity of delirium. The hypoactive and 
hyperactive delirium groups have different patterns noted on autonomic testing. 
Larger studies would improve the statistical reliability of the results. 
 
5.2 Clinical Implication of Results 
The results of this study show an association between delirium and autonomic 
impairment. This relationship may be causal in the development of delirium or may 
be a manifestation of the brain dysfunction that predisposes to, or results from 
delirium. Further longitudinal studies would be required to further evaluate this 
relationship.  
Reverse blood pressure dipping and orthostatic hypertension can reflect sympathetic 
overactivity. Patients with delirium can display clinical features that include insomnia 
and agitation. These are also recognised as features of excess sympathetic activity 
(Castro-Diehl et al. 2016; Lump and Moyer 2014). This raises the possibility that at 
least some of the clinical manifestations of delirium may relate to abnormalities in the 






these signs and symptoms as current pharmacological treatments for delirium, such as 
anti-psychotics, treat behavioural symptoms rather than targeting the cause of the 
symptoms.  
If delirium is related to sympathetic overactive it would be expected that treatment 
with beta-adrenergic blocking agents would have a positive impact on the 
development of delirium and/or the severity or delirium. One study (O'Neal et al. 
2017) compared the incidence of postoperative delirium in patients who did or did not 
receive beta-blockers in the 24-hour period prior to cardiac surgery.  They reported no 
difference in delirium incidence between the two groups. A second study (Tse et al. 
2015) retrospectively identified the risk factors for development of delirium post 
cardiac surgery. Preoperative beta-blocker use was associated with an odds ratio for 
delirium development of 1.7. The use of postoperative beta-blockers was not analysed 
in either of the two studies. If beta-adrenergic blockade was to impact on the 
development of delirium it is likely that persistent treatment during an acute illness 
would be required. It is also important to note that not all beta-blockers have equal 
ability to cross the blood-brain barrier. Highly lipophilic agents such as propranolol 
would have greater CNS activity (McAinsh and Cruickshank 1990) and therefore be 
more likely to have a positive impact on the development of delirium. 
The association between delirium and autonomic impairment provides an interesting 
hypothesis for the benefits of centrally acting selective alpha-2 receptor agonist 
medications for the treatment of delirium. These alpha-2 agonists, such as clonidine 
and dexmedetomidine, inhibit central sympathetic outflow (Giovannitti et al. 2015). 
Dexmedetomidine is an intravenous preparation so its use is largely confined to the 
ICU setting. Its use results in more delirium free days than sedation with lorazepam 
(Pandharipande et al. 2007). The Oslo Study of Clonidine in Elderly Patients with 
Delirium is a randomised controlled trial that is investigating the use of clonidine in 






safe in this population (Hov et al. 2018). If the outcome is positive, it will further 
support role of the autonomic nervous system in delirium. Moxonidine is a I1-
imidazoline receptor agonist that acts in the medulla to reduce sympathetic activity. It 
is used in the treatment of hypertension (Ziegler et al. 1996). Surveillance evidence 
suggests it may cause sedation in some patients (Schachter 1999). It’s impact on 
delirium is not reported. 
Delirium prevention is an important aspect of the clinical care of older adults. By 
identifying at risk individuals, preventative measures can be focused on those who 
require it. If further research confirms the association between delirium and autonomic 
impairment, it may possible to identify individuals at high risk of delirium at their 
initial presentation. Following the initiation of this thesis, Oh et al published the 
findings of their research showing the changes in heart rate variability could be used 
to predict the development of delirium (Oh et al. 2018). 
 
5.3 Possible Vascular Implication of the Results 
Reverse blood pressure dipping is an alteration in the normal circadian blood pressure 
pattern. It is present in approximately 3% of the general population and is more 
commonly seen in those with hypertension. It is associated with markers of end organ 
damage including the development of proteinuria, coronary calcification and left 
ventricular hypertrophy. It is a predictor of the presence of mild carotid plaques and is 
associated with arterial stiffness (Cuspidi et al. 2017). Reverse dipping in delirious 
participants in this study may therefore be a marker of occult cerebrovascular disease. 
Calculation of a cardiovascular risk score may have aided in differentiating between 
the impact of vascular disease and autonomic dysfunction. However, the complete 






Orthostatic hypertension is known to be a risk factor for cardiovascular disease and 
can result in end organ damage including silent cerebrovascular disease (Kario 2013). 
Using brain magnetic resonance imaging (MRI) adults with orthostatic hypertension 
have been found to have more silent infarcts than controls (Eguchi et al. 2004). White 
matter changes and cerebral infarcts are associated with the development of post-
operative delirium (Kant et al. 2017). One of the most common complications 
following symptomatic stroke is the development of delirium (McManus et al. 2007). 
Similar to the reverse dipping status, orthostatic hypertension in delirious participants 
could also relate to cerebrovascular disease. 
 
5.4 Comparison to Autonomic Function in Dementia 
Previous research has investigated for an association between dementia and various 
aspects of autonomic function. Given that dementia is a risk factor for the development 
of delirium (Fong et al. 2009) and patients who have had delirium are at higher risk of 
developing dementia (Davis et al. 2012), autonomic function abnormalities may be 
common to the two conditions. 
Studies have reported an association between dementia and baroreceptor function 
(Meel-van den Abeelen et al. 2013; Saint Martin et al. 2013) and have identified 
reduced baroreflex sensitivity in participants with dementia. This is similar to the 
findings of this study. However, the above two studies did not subdivide baroreceptor 
sensitivity into up and down trends in bloods pressure, as was done in this study. It is 
therefore not possible to ascertain if the dementia studies found impairments related 
to excess or impaired sympathetic activity. 
Another study (Mellingsæter et al. 2015) found a reduction in the sympathetic 






Dementia. This differs from the findings of this research with the tilt and baroreflex 
sensitivity tests suggesting either excess sympathetic activity or reduced 
parasympathetic activity in the delirious population.  
A reverse nocturnal blood pressure dipping status has been associated with worse 
cognitive function as measured using the MoCA (Conway et al. 2015). Reduced 
nocturnal dipping in young adulthood is associated with lower executive function in 
midlife (Yano et al.). Our study also identified a reversed pattern in delirious 
participants. It is possible that the mechanisms that lead to cognitive deficits are 
common to both conditions and may be a marker of the underlying vascular disease 
associated with reverse blood pressure dipping.  
The clinical implications of the above comparisons require further investigation. As 
impaired baroreflex sensitivity and a reverse nocturnal blood pressure pattern appear 
to be common to both conditions, further consideration should be given to ascertaining 
if these measures could be used to identify people who have had delirium and are at 
risk of developing future dementia.  
 
5.5 Strengths of the Study 
This is the first study to look for an association between autonomic impairment and 
delirium outside of the ICU setting. As delirium is very common in the general hospital 
population it is important to include this population in research.  
This is the first study to look at autonomic function markers other than short term (15 
minute) heart rate variability and to incorporate more than one component of 






variability is only one component of autonomic function and important information 
may be missed by looking at it in isolation.  
Delirium diagnosis was based on the DSM-IV criteria which is a delirium diagnostic 
rather than screening tool. The CAM-ICU is a screening tool commonly used in ICU 
studies as a means to identify delirium. This study also used the DRS-R98 which is a 
comprehensive assessment of delirium and allowed for delirium severity to be 
correlated to various autonomic tests, thereby allowing a ‘dose-response’ relationship 
to be evaluated. 
Participants with pre-existing cognitive impairment were identified, thereby allowing 
the impact of this to be excluded. This is important because as discussed in Chapter 4 
and Section 5.4 of this thesis, autonomic function differs in those with delirium and 
dementia. 
Delirium subtype was characterised in this study. Although the sample size is not large 
enough to draw definite conclusions, the results do open the possibility that autonomic 
function may vary according to delirium subtype. 
Autonomic function testing took place when participants were free of acute illness. 
This helped to minimise the impact that other acute conditions would have on the 
results. 
The population enrolled in this study were largely an older, frailer population, which 







5.6 Weaknesses of the Study 
This study is limited by the small sample. This may have led to a type 1 error in the 
Head-Up tilt test, baroreflex sensitivity, 24-hour blood pressure variability and diurnal 
blood pressure variability components of the study. Many results are however 
consistent throughout the study.  
The small sample size may have also caused a type 2 error in the heart rate variability 
component of the study, suggesting no relationship when there truly is one.  
Recruitment and follow up difficulties were encountered during the course of the 
study. This was largely due to the older age included, the high prevalence of frailty in 
the study population and the morbidity and mortality associated with delirium. The 
participants who did not attend follow-up had higher illness severity scores during 
their initial admission. The population included does however reflect the population 
at highest risk of developing delirium and it is important to include this group in any 
delirium research study. 
Selection bias may have occurred by only including participants who were already 
under the care of a consultant geriatrician. Using this selection criterion ensured 
sufficient follow up of any abnormalities identified during the study, which is 
important for ethical reasons.  
Delirium testing took place at one-time point only which may have led to participants 
being wrongly classified as not having delirium. In order to minimise this risk, the 
medical and nursing notes were reviewed for evidence of delirium and collateral 






Although race was not included in the inclusion or exclusion criteria, all participants 
were recruited in Ireland and were Irish. This may limit the generalisability to other 
populations. No participants were in ICU or receiving end of life care. Delirium is 
very common in both of these settings but the results of this study may not apply to 
these patients. 
Many of the limitations of the study are expected when studying a population with 
delirium. Despite these limitations this study provides a novel theory to explain the 
complex pathophysiology underlying an understudied topic.  
 
5.7 Directions for Future Study 
This study presents new hypotheses on which to base future research in delirium.  
A larger study would be required to confirm the associations between sympathetic 
over-activity and delirium identified in this study. The results outlined in Chapter 4 
were used to carry out post hoc sample size calculations that could be used to ensure 
sufficient power for future studies (Table 21). 
Table 21: Post Hoc Sample Size Calculations 
Autonomic Function Test Number of Participants Required 
Change in Systolic Blood Pressure on 
Head-Up Tilt 
44 
Supine Baroreflex Effectiveness Index 46 
Erect Baroreflex Effectiveness Index 62 
Low Frequency Heart Rate Variability 86 
High Frequency Heart Rate Variability 132 
Average Real Variability of Blood 
Pressure 
114 






A similar study would however only have the potential to confirm an association 
between autonomic impairment and delirium. In order to ascertain if autonomic 
impairment is causative in the development of delirium, a longitudinal cohort study 
would be required. Participants with normal cognition and no history of delirium 
would need to be recruited, have autonomic function testing carried out at the onset of 
the study and be followed up for the future development of delirium or changes in 
autonomic function.  
As outlined previously, some of the associations between autonomic impairment and 
delirium may relate to cerebrovascular disease. It is therefore important that future 
studies would have a measure of cerebrovascular disease included, such as magnetic 
resonance imaging of the brain. 
The comparisons between hyperactive and hypoactive delirium provide a hypothesis 
that the clinical features of the different delirium subtypes may relate to autonomic 
function. Confirmation of this should be a focus of future research as it may identify 
different treatment targets for different subtypes. Targeting delirium treatment towards 
treatment of underlying autonomic dysfunction would however pose a challenge as 
current treatments are largely targeted at symptoms control. Equally, preventing the 
development of autonomic impairment is difficult due to the multitude of underlying 
causes. 
Given the interrelationship between delirium and dementia, future studies of 
autonomic function should involve both conditions and attempt to identify if particular 
characteristics of autonomic function could be used to identify patients with delirium 
who are at risk of developing dementia.  
This study encountered a number of issues with recruitment and follow-up. Future 






database of autonomic function tests carried out over several years. One potential 
method of reducing follow-up difficulties would be to retrospectively review the 
results of these tests and carry out a chart review to determine future development of 
delirium. Potential difficulties with this would however include the lack of 
standardised delirium diagnostic tools in clinical practice and compliance with the 









This thesis presented research that investigated for an association between delirium 
and autonomic impairment. This was a novel approach to attempting to identify the 
underlying pathophysiology of a common but poorly understood condition. The 
results of this study show that there is an association between delirium and autonomic 
impairment with differences detected between the delirium and control groups with 
regard to orthostatic blood pressure changes, baroreflex sensitivity, diurnal blood 
pressure variability and 24-hour blood pressure variability. The results differ from 
some of the findings of previous research investigating the relationship between 
dementia and autonomic impairment, suggesting differences in autonomic function in 
delirium and dementia. As one of the first studies of its kind, this study provides new 
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Appendix A: Patient Consent Form 
Investigating the Relationship between Autonomic Dysfunction, Delirium and 
Sarcopenia 
If you wish to take part in this study please ensure that you have read the information 
leaflet that you were given. When you are satisfied that you understand the leaflet, 
what the study entails and that all your questions have been answered please proceed 
to complete this form which gives your permission take part in this study. 
Please tick that you have read and agree with the following: 
 
I understand the information presented in the information 
leaflet 
 
Yes  □ 
 
No □ 
All my questions have been satisfactorily answered  Yes  □ No □ 
I understand that participation in the study is voluntary 
and can be withdrawn at any time 
Yes  □ No □ 
I agree for my medical notes to be reviewed for necessary 
information such as my past medical history and 
medications 
Yes  □ No □ 
 
I give permission for an anonymized version of my test 
results to be recorded and used for the purposes of the 
study 
Yes  □ No □ 
 
I understand that a record of the necessary results will be 
recorded in my medical notes and my GP or consultant 
may be informed of the results 
  
Yes  □ No □ 
 
I agree to participate in this study 
 
Yes  □ No □ 







Participants Name: ______________________________________ 
Signature of Participant:__________________________________ 
Date:______________ 









Appendix B: Family Member Consent Form 
Investigating the Relationship between Autonomic Dysfunction, Delirium and 
Sarcopenia 
If you wish for your family member to take part in this study, please ensure that you 
have read the information leaflet that you were given. When you are satisfied that 
you understand the leaflet, what the study entails and that all your questions have 
been answered please proceed to complete this form which gives your permission for 
your family member to take part in this study. 
Please tick that you have read and agree with the following: 
 
I understand the information presented in the 
information leaflet 
 
Yes  □ 
 
No □ 
All my questions have been satisfactorily answered  Yes  □ No □ 
I understand that participation in the study is voluntary 
and can be withdrawn at any time 
Yes  □ No □ 
I agree for my family member’s medical notes to be 
reviewed for necessary information such as their past 
medical history and medications 
Yes  □ No □ 
I give permission for an anonymized version of the test 
results to be recorded and used for the purposes of the 
study 
Yes  □ No □ 
 
I understand that a record of the necessary results will be 
recorded in their medical notes and their GP or 
consultant may be informed of the results 
  
Yes  □ No □ 
 
I agree to my family member participating in this study 
 
Yes  □ No □ 







Participants Name: ______________________________________ 
Family Members Name:___________________________________ 
Relationship to Participant:_________________________________ 
Signature of Family Member:_______________________________ 
Date:______________ 








Appendix C: Patient and Family Information Sheet 
Investigating the Relationship between Autonomic Dysfunction, 
Delirium and Sarcopenia 
Introduction 
Delirium is a condition characterised by acute confusion, poor attention and a change 
in alertness. It is very common in older people admitted to hospital. It can occur in a 
number of conditions including infection, constipation or a change in medications. 
However the underlying mechanism by which it occurs is not understood. A medical 
study is currently being carried out in this hospital to investigate for possible 
mechanisms. 
In order for any organ to function correctly it must have sufficient blood flow. The 
blood flow to the brain is controlled in part by part of the nervous system called the 
Autonomic Nervous System. We want to investigate if dysfunction in this system 
could be associated with delirium. 
Sarcopenia is a condition where the body loses muscle mass. It is more common as a 
person gets older. Previous research has shown that it is associated with dementia. 
We want to investigate if it is associated with delirium. 
 
Procedures 
Patients who take part in the study will have the presence or absence of delirium 
confirmed using a set of memory tests. A family member will be contacted to ask 
about any previous confusion or memory problems. The results of these tests will be 
recorded in the participant’s medical notes. Any tests carried out by your consultant 
as part of your routine care and any diagnosis made will be recorded for the study. 
All participants will be asked to attend for an outpatient appointment after discharge. 
The memory tests will be repeated. The Autonomic Nervous System will be tested 
by using standard tests for this purpose- a 24 hour blood pressure monitor, a 24 hour 
heart monitor (holter) and a tilt table test that tests the heart rate and blood pressure 
response to changes in posture. The heart and blood pressure monitor are worn home 
and returned by a family member the following day. To look at body muscle mass a 
scan called a whole body DEXA scan will be carried. This does not involve exposure 






Participants may be asked to attend for further follow up if required. 
Taking part in this study will not affect the treatment and investigations that 
participants would otherwise receive from medical and nursing staff.  
 
Benefits 
All participants will be checked for the presence of delirium. If detected this will 
allow the medical staff looking after you to adequately treat it. 
All participants will have a thorough evaluation of memory function, blood pressure 
and heart rhythm and might not otherwise be carried out. 
Participating in this study will help to further medical knowledge and may help to 
treat future patients with delirium.  
Risks 
People with delirium can sometimes become agitated if presented with a task they 
find difficult. If this occurs the test will be stopped. 
The blood pressure monitor can be tight on your arm and some people find it hard to 
sleep because of it. It can be removed at home if necessary. 
Exclusion from Participation 
• Participants under the age of 65 are less likely to have delirium and are 
therefore excluded 
• Patients with confusion due to alcohol or substance withdrawal as the 
underlying mechanism of delirium may be different 
• Uncontrolled depression or recent stroke, heart attack or brain tumour as this 
may affect the results 
• Unable to comply with the tests 
• Patients whose consultant feels they are too sick to take part 
 
Confidentiality 
All personal information is confidential. Your name will not be attached to any data. 
All participants’ names will be written in a log book and matched with an 






identification code will be used on all assessment sheets. All data will be stored in a 
secure location. A copy of the assessment will be recorded in the participant’s 
medical notes.  
Compensation 
This study is a non-profit study and we are therefore unable to provide any financial 
compensation to participants. 
Voluntary Participation and Stopping the Study 
All participation in the study is on a voluntary basis and will only be done with 
permission from the participant or their next-of-kin if they are unable to give 
permission themselves. Refusal to participate will not affect the level of care 
received. Participation in the study can be withdrawn at any time if you no longer 
wish for you/your family member to continue. 
Permission 
You will be asked to sign a form to state that you give permission for you/your 
family member to take part in this study. This includes permission for an 
anonymized version of your test results to be used as part of the study. If you are 
giving permission on behalf of your family member you are asked to give this leaflet 
to them when they are better. Permission can then be withdrawn if they wish. 
Complaints Procedure 
If you have any concerns or complaints regarding this study you may contact the 
researcher below. 
Contact Information 
If you have any queries you may contact the researcher: 
Dr. Elaine Shanahan   
Clinical Age Assessment Unit 








Appendix D: Delirium Rating Scale Revised 1998 (DRS-R98) 
SEVERITY SCALE 
1. Sleep-wake cycle disturbance 
Rate sleep-wake pattern using all sources of information, including from family, 














2. Perceptual disturbances and hallucinations 
Illusions and hallucinations can be of any sensory modality. Misperceptions are 
“simple” if they are uncomplicated, such as a sound, noise, color, spot, or flashes and 
“complex” if they are multidimensional, such as voices, music, people, animals, or 
scenes. Rate if reported by patient or caregiver, or inferred by observation. 
 
0 not present 
1 mild sleep continuity disturbance at night or occasional 
drowsiness during the day  
2 moderate disorganization of sleep-wake cycle (eg, falling asleep 
during conversations, napping during the day or several brief 
awakenings during the night with confusion/behavioral changes 
or very little nighttime sleep) 
3 severe disruption of sleep-wake cycle (eg, day-night reversal of 
sleep-wake cycle or severe circadian fragmentation with 










0 Not present 
1 mild perceptual disturbances (eg, feelings of derealization or 
depersonalization; or patient may not be able to discriminate 
dreams from reality)  
2 illusions present  




Delusions can be of any type, but are most often persecutory. Rate if reported by 
patient, family or caregiver. Rate as delusional if ideas are unlikely to be true yet are 
believed by the patient who cannot be dissuaded by logic. Delusional ideas cannot be 
explained otherwise by the patient’s usual cultural or religious background. 
0 Not present 
1 mildly suspicious, hypervigilant, or preoccupied  
2 unusual or overvalued ideation that does not reach delusional 







4. Lability of affect 
Rate the patient’s affect as the outward presentation of emotions and not as a 















Rate abnormalities of spoken, written or sign language that cannot be otherwise 
attributed to dialect or stuttering. Assess fluency, grammar, comprehension, semantic 
content and naming. Test comprehension and naming nonverbally if necessary by 




0 Not present 
1 affect somewhat altered or incongruent to situation; changes 
over the course of hours; emotions are mostly under self-
control 
2 affect is often inappropriate to the situation and intermittently 
changes over the course of minutes; emotions are not 
consistently under self-control, though they respond to 
redirection by others 
3  severe and consistent disinhibition of emotions; affect changes 
rapidly, is inappropriate to context, and does not respond to 

















6. Thought process abnormalities 
Rate abnormalities of thinking processes based on verbal or written output. If a 









0 Normal language 
1 Mild impairment including word-finding difficulty or problems 
with naming or fluency  
2 Moderate impairment including comprehension difficulties or 
deficits in meaningful communication (semantic content)  
3 Severe impairment including nonsensical semantic content, 
word salad, muteness, or severely reduced comprehension 
0 Normal thought processes  
1 Tangential or circumstantial  
2 Associations loosely connected occasionally, but largely 
comprehensible  






7. Motor agitation 
Rate by observation, including from other sources of observation such as by visitors, 











8. Motor retardation 
Rate movements by direct observation or from other sources of observation such as 
family, visitors, or clinical staff. Do not rate components of retardation that are 






0 No restlessness or agitation  
1 Mild restlessness of gross motor movements or mild 
fidgetiness.  
2 Moderate motor agitation including dramatic movements of the 
extremities, pacing, fidgeting, removing  intravenous lines, 
etc.  
3 Severe motor agitation, such as combativeness or a need for 






0 No slowness of voluntary movements  
1 Mildly reduced frequency, spontaneity or speed of motor 
movements, to the degree that may interfere somewhat with the 
assessment.  
2 Moderately reduced frequency, spontaneity or speed of motor 
movements to the degree that it interferes with participation in 
activities or self-care.  
3 Severe motor retardation with few spontaneous movements.  
 
9. Orientation 
Patients who cannot speak can be given a visual or auditory presentation of multiple 
choice answers. Allow patient to be wrong by up to 7 days instead of 2 days for 
patients hospitalized more than 3 weeks. Disorientation to person means not 
recognizing familiar persons and may be intact even if the person has naming 
difficulty but recognizes the person. Disorientation to person is most severe when 
one doesn’t know one’s own identity and is rare. Disorientation to person usually 








0 Oriented to person, place and time.  
1 Disoriented to time (eg, by more than 2 days or wrong month or 
wrong year) or to place (eg, name of building, city, state), but 
not both 
2 Disoriented to time and place  







Patients with sensory deficits or who are intubated or whose hand movements are 
constrained should be tested using an alternate modality besides writing. Attention 
can be assessed during the interview (eg, verbal perseverations, distractibility, and 












11. Short-term memory 
Defined as recall of information (eg, 3 items presented either verbally or visually) 
after a delay of about 2 to 3 minutes. When formally tested, information must be 
registered adequately before recall is tested. The number of trials to register as well 
as effect of cueing can be noted on scoresheet. Patient should not be allowed to 
rehearse during the delay period and should be distracted during that time. Patient 
may speak or nonverbally communicate to the examiner the identity of the correct 
items. Short-term deficits noticed during the course of the interview can be used 
also. 
0 Alert and attentive.  
1 Mildly distractible or mild difficulty sustaining attention, but 
able to refocus with cueing. On formal testing makes only 
minor errors and is not significantly slow in responses.  
2 Moderate inattention with difficulty focusing and sustaining 
attention. On formal testing, makes numerous errors and 
either requires prodding to focus or finish the task.  
3 Severe difficulty focusing and/or sustaining attention, with 
many incorrect or incomplete responses or inability to 
follow instructions. Distractible by other noises or events in 
















12. Long-term memory 
Can be assessed formally or through interviewing for recall of past personal (eg, past 
medical history or information or experiences that can be corroborated from another 
source) or general information that is culturally relevant. When formally tested, use a 
verbal and/or visual modality for 3 items that are adequately registered and recalled 
after at least 5 minutes. The patient should not be allowed to rehearse during the 
delay period during formal testing. Make allowances for patients with less than 8 
years of education or who are mentally retarded regarding general information 
questions. Rating of the severity of deficits may involve a judgement about all the 
ways long-term memory is assessed, including recent and/or remote long-term 
memory ability informally tested during the interview as well as any formal testing 
of recent long-term memory using 3 items. 
 
 
0 Short-term memory intact.  
1 Recalls 2/3 items; may be able to recall third item after 
category cueing.  
2 Recalls 1/3 items; may be able to recall other items after 
category cueing.  
















13. Visuospatial ability 
Assess informally and formally. Consider patient’s difficulty navigating one’s way 
around living areas or environment (eg, getting lost). Test formally by drawing or 
copying a design, by arranging puzzle pieces, or by drawing a map and identifying 









0 No significant long-term memory deficits  
1 Recalls 2/3 items and/or has minor difficulty recalling details of 
other long-term information  
2 Recalls 1/3 items and/or has moderate difficulty recalling other 
long-term information  
3 Recalls 0/3 items and/or has severe difficulty recalling other 







0 No impairment  
1 Mild impairment such that overall design and most details or pieces are 
correct; and/or little difficulty navigating in his/her surroundings  
2 Moderate impairment with distorted appreciation of overall design and/or 
several errors of details or pieces; and/or needing repeated redirection to 
keep from getting lost in a newer environment despite, trouble locating 
familiar objects in immediate environment  
3 Severe impairment on formal testing; and/or repeated wandering or 
getting lost in environment  
 
 
DRS-R98 DIAGNOSTIC ITEMS 
These three items can be used to assist in the differentiation of delirium from other 
disorders for diagnostic and research purposes. They are added to the severity score 
for the total scale score, but are NOT included in the severity score. 
 
14. Temporal onset of symptoms 
Rate the acuteness of onset of the initial symptoms of the disorder or episode being 
currently assessed, not their total duration. Distinguish the onset of symptoms 
attributable to delirium when it occurs concurrently with a different preexisting 
psychiatric disorder. For example, if a patient with major depression is rated during a 
















15. Fluctuation of symptom severity 
Rate the waxing and waning of an individual or cluster of symptom(s) over the time 
frame being rated. Usually applies to cognition, affect, intensity of hallucinations, 
thought disorder, language disturbance. Take into consideration that perceptual 
disturbances usually occur intermittently, but might cluster in period of greater 








0 no significant change from usual or longstanding baseline 
behavior  
1 gradual onset of symptoms, occurring over a period of several 
weeks to a month  
2 acute change in behavior or personality occurring over days to a 
week  
3 abrupt change in behavior occurring over a period of several 
hours to a day  
0 no symptom fluctuation 
1 symptom intensity fluctuates in severity over hours  






16. Physical disorder 
Rate the degree to which a physiological, medical or pharmacological problem can 
be specifically attributed to have caused the symptoms being assessed. Many patients 
have such problems but they may or may not have causal relationship to the 

















0 none present or active  
1 presence of any physical disorder that might affect mental state  
2 drug, infection, metabolic disorder, CNS lesion or other 
medical problem that specifically can be implicated in causing 











Remember, “Yes, a change” indicates 
that there has been a change in the last 
several years caused by cognitive 
(thinking and memory) problems.   
                                                                           
  
YES,  




No change  




Don’t know  
  
1. Problems with judgment (e.g., 
problems making decisions, bad financial 
decisions, problems with thinking)  
   
2. Less interest in hobbies/activities  
  
  
      
3. Repeats the same things over and over 
(questions, stories, or  
statements)  
  
      
4. Trouble learning how to use a tool, 
appliance, or gadget (e.g., VCR, 
computer, microwave, remote control)   
      
5. Forgets correct month or year  
  
  
      
6. Trouble handling complicated 
financial affairs (e.g., balancing 
checkbook, income taxes, paying bills)  
  
      
7. Trouble remembering appointments  
   
8. Daily problems with thinking and/or 
memory  
      
TOTAL AD8 SCORE  
  
       






The AD8 Administration and Scoring Guidelines  
A spontaneous self-correction is allowed for all responses without counting as an 
error.  
The questions are given to the respondent on a clipboard for self–administration or 
can be read aloud to the respondent either in person or over the phone. It is preferable 
to administer the AD8 to an informant, if available.  If an informant is not available, 
the AD8 may be administered to the patient.   
When administered to an informant, specifically ask the respondent to rate change in 
the patient.    
When administered to the patient, specifically ask the patient to rate changes in his/her 
ability for each of the items, without attributing causality.   
If read aloud to the respondent, it is important for the clinician to carefully read the 
phrase as worded and give emphasis to note changes due to cognitive problems (not 
physical problems). There should be a one second delay between individual items.  
  
No timeframe for change is required.  
The final score is a sum of the number items marked “Yes, A change”.  
  
 
Interpretation of the AD8  
(Adapted from Galvin JE et al, The AD8, a brief informant interview to detect 
dementia, Neurology 2005:65:559-564)  
  
A screening test in itself is insufficient to diagnose a dementing disorder. The AD8 






common dementing illness including Alzheimer disease, vascular dementia, Lewy 
body dementia and frontotemporal dementia.   
  
Scores in the impaired range (see below) indicate a need for further assessment. 
Scores in the “normal” range suggest that a dementing disorder is unlikely, but a 
very early disease process cannot be ruled out. More advanced assessment may be 
warranted in cases where other objective evidence of impairment exists.  
  
Based on clinical research findings from 995 individuals included in the 
development and validation samples, the following cut points are provided:  
• 0 – 1:  Normal cognition  
• 2 or greater: Cognitive impairment is likely to be present    
 
Administered to either the informant (preferable) or the patient, the AD8 has the 
following properties:  
• Sensitivity > 84%  
• Specificity > 80%  
• Positive Predictive Value > 85%  
• Negative Predictive Value > 70%  
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Appendix F: Charlson Comorbidity Index 
Each item below receives 1 point unless stated otherwise 
1. Myocardial Infarction 
2. Congestive Heart Failure 
3. Peripheral Vascular Disease 
4. Cerebrovascular Disease 
5. Dementia 
6. COPD 
7. Connective Tissue Disease 
8. Peptic Ulcer Disease 
9. Diabetes Mellitus (1 point uncomplicated, 2 points if end-organ damage) 
10. Moderate to Severe Chronic Kidney Disease (2 points) 
11. Hemiplegia (2 points) 
12. Leukemia (2 points) 
13. Malignant Lymphoma (2 points) 
14. Solid Tumor (2 points, 6 points if metastatic) 
15. Liver Disease (1 point mild, 3 points if moderate to severe) 




1. Age <40 years: 0 points 
2. Age 41-50 years: 1 point 
3. Age 51-60 years: 2 points 
4. Age 61-70 years: 3 points 











Appendix G: APACHE II Severity of Disease Classification System 
Physiologic Variable High Abnormal Range                                                      Low Abnormal Range 
  +4 +3 +2 +1 0 +1 +2 +3 +4 Points 
Temperature - rectal (°C) >41° 39 to 
40.9° 











<29.9°   








  70 to 
109 
  50 to 
69 
  <49   








  70 to 
109 








>50 35 to 
49 
  25 to 
34 
12 to 24 10 to 
11 
6 to 9   <5   
Oxygenation: A-
aDO2 orPaO2 (mm Hg) 
a. FIO2 >0.5 record A-
aDO2 




































Arterial pH (preferred) 
  
Serum HCO3 (venous 
mEq/l) 
(not preferred, but may use 





















































<110   
Serum Potassium (mEq/l) >7 6 to 
6.9 








  <2.5   
Serum Creatinine (mg/dl) 
Double point score for 
acute renal failure 




  0.6 to 
1.4 
  <0.6       






  20 to 
29.9 
  <20   
White Blood Count 
(total/mm3) 
(in 1000s) 






  1 to 
2.9 
  <1   
Glasgow Coma Score 
(GCS) 
Score = 15 minus actual 
GCS 
                    
A. Total Acute Physiology Score (sum of 12 above points)   
B. Age points (years) <44=0; 45 to 54=2; 55 to 64=3; 65 to 74=5; >75=6   
C. Chronic Health Points (see below)   







Chronic Health Points: If the patient has a history of severe organ system insufficiency or is 
immunocompromised as defined below, assign points as follows: 
5 points for nonoperative or emergency postoperative patients 
2 points for elective postoperative patients 
Definitions: organ insufficiency or immunocompromised state must have been evident prior to this hospital 
admission and conform to the following criteria: 
• Liver – biopsy proven cirrhosis and documented portal hypertension; episodes of past upper GI 
bleeding attributed to portal hypertension; or prior episodes of hepatic 
failure/encephalopathy/coma. 
• Cardiovascular – New York Heart Association Class IV. 
• Respiratory – Chronic restrictive, obstructive, or vascular disease resulting in severe exercise 
restriction (i.e., unable to climb stairs or perform household duties; or documented chronic hypoxia, 
hypercapnia, secondary polycythemia, severe pulmonary hypertension (>40 mmHg), or respirator 
dependency. 
• Renal – receiving chronic dialysis. 
• Immunocompromised – the patient has received therapy that suppresses resistance to infection 
(e.g., immunosuppression, chemotherapy, radiation, long term or recent high dose steroids, or has 
a disease that is sufficiently advanced to suppress resistance to infection, e.g., leukemia, 
lymphoma, AIDS). 
Interpretation of Score: 

















Appendix H: Frailty Index 
  
Change in activities of 
daily living 
Abnormal sleep Headaches 
Head and neck condition Restlessness Cardiovascular disease 
Incontinence Short term memory 
difficulties 
Stroke 
GIT problems Long term memory 
impairment 
Diabetes 




Paranoia Cerebrovascular disease 
Falls Parkinson’s disease Myocardial infarction 
Mood disturbance Seizure disorder Arrhythmia 
Congestive cardiac 
failure 
Respiratory disease Thyroid disease 
Skin problems Malignancy Breast disease 






Appendix I: Barthel Index 
 
 
Patient Name:  
 
___________________________  
 Rater Name:  ___________________________  
 
  
Date:  ___________________________  
Activity   Score  
  
FEEDING  
0 = unable  
5 = needs help cutting, spreading butter, etc.,  
      or requires modified diet  
10 = independent                                                      _____  
 
BATHING  
0 = dependent  
 5 = independent (or in shower)                      _____ 
   
GROOMING   
0 = needs to help with personal care  
 5 = independent face/hair/teeth/shaving (implements provided)    _____ 
  
DRESSING  
0 = dependent  
5 = needs help but can do about half unaided  
 10 = independent (including buttons, zips, laces, etc.)      _____ 
   
  
BOWELS  
0 = incontinent (or needs to be given enemas)  
5 = occasional accident  
 10 = continent                                                    _____ 
   
  
BLADDER  
0 = incontinent, or catheterized and unable to manage alone  
5 = occasional accident  








TOILET USE  
0 = dependent  
5 = needs some help, but can do something alone  
 10 = independent (on and off, dressing, wiping)               _____ 
  
  
TRANSFERS (BED TO CHAIR AND BACK)  
0 = unable, no sitting balance  
5 = major help (one or two people, physical), can sit  
10 = minor help (verbal or physical)  
 15 = independent                 _____ 
  
 
MOBILITY (ON LEVEL SURFACES)  
0 = immobile or < 50 yards  
5 = wheelchair independent, including corners, > 50 yards  
10 = walks with help of one person (verbal or physical) > 50 yards  
 15 = independent (but may use any aid; for example, stick) > 50 yards  




0 = unable  
5 = needs help (verbal, physical, carrying aid)  





 TOTAL (0–100): ______  








The Barthel ADL Index: Guidelines 
1. The index should be used as a record of what a patient does, not as a 
record of what a patient could do.   
2. The main aim is to establish degree of independence from any help, 
physical or verbal, however minor and for whatever reason.   
3. The need for supervision renders the patient not independent.   
4. A patient's performance should be established using the best available 
evidence. Asking the patient, friends/relatives and nurses are the usual 
sources, but direct observation and common sense are also important. 
However direct testing is not needed.   
5. Usually the patient's performance over the preceding 24-48 hours is 
important, but occasionally longer periods will be relevant.   
6. Middle categories imply that the patient supplies over 50 per cent of the 
effort.   
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The Maryland State Medical Society holds the copyright for the Barthel Index.  It 
may be used freely for noncommercial purposes with the following citation:  
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Permission is required to modify the Barthel Index or to use it for commercial 
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